

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM693942

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
MESOBLAST LIMITED ACN 109 431 870		11/19/2021	Listed Public Company: AUSTRALIA
MESOBLAST UK LIMITED		11/19/2021	Company: ENGLAND AND WALES
MESOBLAST, INC. (formerly known as Angioblast, Inc.)		11/19/2021	Corporation: DELAWARE
MESOBLAST INTERNATIONAL SÀRL		11/19/2021	Company: SWITZERLAND

RECEIVING PARTY DATA

Name:	OAKTREE FUND ADMINISTRATION, LLC
Street Address:	333 S. GRAND AVENUE, 28TH FLOOR
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90071
Entity Type:	Limited Liability Company: DELAWARE

PROPERTY NUMBERS Total: 7

Property Type	Number	Word Mark
Registration Number:	3393731	MESOBLAST
Registration Number:	4494438	MESOBLAST
Registration Number:	4045644	REVASCOR
Registration Number:	6160286	RYONCIL
Registration Number:	6176867	
Serial Number:	88317318	RYONCIL
Serial Number:	88346971	

CORRESPONDENCE DATA

Fax Number: 2029567069

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2029567685

Email: carrierr@sullcrom.com, nguyenb@sullcrom.com

Correspondent Name: Rita M. Carrier

TRADEMARK

Address Line 1: 1700 New York Avenue, N.W., Suite 700
Address Line 2: Sullivan & Cromwell LLP
Address Line 4: Washington, D.C. 20006-5215

NAME OF SUBMITTER: RITA M. CARRIER

SIGNATURE: /RITA M. CARRIER/

DATE SIGNED: 12/10/2021

Total Attachments: 79

source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page1.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page2.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page3.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page4.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page5.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page6.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page7.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page8.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page9.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page10.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page11.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page12.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page13.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page14.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page15.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page16.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page17.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page18.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page19.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page20.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page21.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page22.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page23.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page24.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page25.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page26.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page27.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page28.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page29.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page30.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page31.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page32.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page33.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page34.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page35.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page36.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page37.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page38.tif
source=Mesoblast - Intellectual Property Security Agreement [Executed] (4864-0624-4868.1)#page39.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (“Agreement”) dated as of November 19, 2021, is made by MESOBLAST LIMITED ACN 109 431 870, an Australian listed public company (“Parent”), MESOBLAST UK LIMITED, a company incorporated in England and Wales with registered number 07596260 whose registered address is 5 New Street Square, London, EC4A 3TW, United Kingdom (“Mesoblast UK”), MESOBLAST, INC. (formerly known as Angioblast, Inc.), a Delaware corporation (“Mesoblast USA”), MESOBLAST INTERNATIONAL SARL, a company organized under the laws of Switzerland (“Mesoblast SUI” and, individually and collectively with Parent, Mesoblast UK, and Mesoblast USA, the “Grantor”), in favor of OAKTREE FUND ADMINISTRATION, LLC, a Delaware limited liability company, in its capacity as administrative agent and collateral agent for itself and the Lenders (as defined below) (in such capacity, the “Agent”).

RECITALS

A. Grantor has entered into a Loan Agreement and Guaranty with certain financial institutions party thereto (the “Lenders”) and Agent, in its capacity as administrative agent and collateral agent for itself and the Lenders, dated as of November 19, 2021 (as amended, restated, or otherwise modified from time to time, the “Loan Agreement”). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent for its benefit and the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor hereby grants and pledges to Agent, for its benefit and the benefit of the Lenders, a continuing security interest in all of Grantor’s right, title and interest in, to and under the Intellectual Property Collateral, including, without limitation, the following:

(a) Any and all Copyrights and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held and all in-bound exclusive Copyright Licenses for any of the foregoing, including without limitation those Copyrights and in-bound exclusive Copyright Licenses set forth on Exhibit A attached hereto;

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All Patents and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto;

(e) Any Trademarks and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such Trademarks, including without limitation those set forth on Exhibit C attached hereto;

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All Licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing or anything herein to the contrary, in no event shall the Intellectual Property Collateral include the following: (i) any Excluded Property, and (ii) any “intent to use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Limitation of Security. Notwithstanding anything to the contrary in this Agreement, the obligations of Mesoblast SUI or any other Grantor incorporated in Switzerland

(collectively, the “Swiss Grantor”) and the rights of the Agent under this Agreement are subject to the following limitations:

- a. If and to the extent the security interest granted by the Swiss Grantor under this Agreement secures obligations of its (direct or indirect) parent company (upstream security) or its sister companies (cross-stream security) (the “Upstream or Cross-Stream Secured Obligations”) and if and to the extent using the proceeds from the enforcement of such security interest to discharge the Upstream or Cross-Stream Secured Obligations would constitute a repayment of capital (*Einlagerückgewähr/Kapitalrückzahlung*), a violation of the legally protected reserves (*gesetzlich geschützte Reserven*) or the payment of a (constructive) dividend (*Gewinnausschüttung*) under Swiss corporate law or would otherwise be restricted under Swiss law and practice then applicable, the proceeds from the enforcement of such security interest to be used to discharge the Upstream or Cross-Stream Secured Obligations shall be limited to the maximum amount of the Swiss Grantor's freely disposable shareholder or quotaholder equity at the time of enforcement (the “Maximum Amount”); provided that such limitation is required under the applicable law at that time; provided, further, that such limitation shall not free the Swiss Grantor from its obligations in excess of the Maximum Amount, but merely postpone the performance date of those obligations until such time or times as performance is again permitted under then applicable law. This Maximum Amount of freely disposable shareholder or quotaholder equity shall be determined in accordance with Swiss law and applicable Swiss accounting principles, and, if and to the extent required by applicable Swiss law, shall be confirmed by the auditors of the Swiss Grantor on the basis of an interim audited balance sheet as of that time.
- b. In respect of Upstream or Cross-Stream Secured Obligations, the Swiss Grantor shall, as concerns the proceeds resulting from the enforcement of the security interest under this Agreement, if and to the extent required by applicable law in force at the relevant time:
 - i. procure that such enforcement proceeds can be used to discharge Upstream or Cross-Stream Secured Obligations without deduction of Swiss Withholding Tax by discharging the liability to such tax by notification pursuant to applicable law rather than payment of the tax. To the extent the proceeds are received directly by the Agent, the latter shall deduct and pay such taxes to, in its sole discretion, either (i) the Swiss Federal Tax Administration or (ii) the Swiss Grantor (in order for the Swiss Grantor to pay the taxes to the Swiss Federal Tax Administration itself).
 - ii. if the notification procedure pursuant to sub-paragraph (i) above does not apply, deduct the Swiss Withholding Tax at such rate (currently 35% at the date of this Agreement) as is in force from time to time from any such enforcement proceeds used to discharge Upstream or Cross-Stream

- Secured Obligations, and pay, without delay, any such taxes deducted to the Swiss Federal Tax Administration;
- iii. notify the Agent that such notification or, as the case may be, deduction has been made, and provide the Agent with evidence that such a notification of the Swiss Federal Tax Administration has been made or, as the case may be, such taxes deducted have been paid to the Swiss Federal Tax Administration; and
 - iv. in the case of a deduction of Swiss Withholding Tax, use its reasonable efforts to ensure that any person, which is entitled to a full or partial refund of the Swiss Withholding Tax deducted from such enforcement proceeds, will, as soon as possible after such deduction,
 - 1. request a refund of the Swiss Withholding Tax under applicable law (including tax treaties), and
 - 2. pay to the Agent upon receipt any amount so refunded.
- c. The Swiss Grantor shall promptly take and promptly cause to be taken any action, including the following:
- i. the passing of any shareholders' or quotaholders' resolutions to approve the use of the enforcement proceeds, which may be required as a matter of Swiss mandatory law in force at the time of the enforcement of the security interest in order to allow a prompt use of the enforcement proceeds;
 - ii. preparation of up-to-date audited balance sheet of the Swiss Grantor ;
 - iii. confirmation of the auditors of the Swiss Grantor that the relevant amount represents the Maximum Amount;
 - iv. conversion of restricted reserves into profits and reserves freely available for the distribution as dividends (to the extent permitted by mandatory Swiss law);
 - v. revaluation of hidden reserves (to the extent permitted by mandatory Swiss law);
 - vi. to the extent permitted by applicable law, Swiss accounting standards and the Loan Agreement, write-up or realize any of its assets that are shown in its balance sheet with a book value that is significantly lower than the market value of the assets, in case of realization, however, only if such assets are not necessary for the Swiss Grantor's business (*nicht betriebsnotwendig*); and
 - vii. all such other measures necessary to allow the Swiss Grantor to use enforcement proceeds as agreed hereunder with a minimum of limitations.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

6. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.


7. Governing Law; Consent to Jurisdiction and Venue. This Agreement has been negotiated and delivered to Agent in the State of New York, and shall have been accepted by Agent in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. Consent to Jurisdiction and Venue. Save to the extent expressly provided for in any Loan Document to the contrary, all judicial proceedings (to the extent that the reference requirement of Section 11.11 is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state or federal court located in the State of New York. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in New York County, State of New York; (b) waives any objection as to jurisdiction or venue in New York County, State of New York; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement or the other Loan Documents.


[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

MESOBLAST LIMITED ACN 109 431 870

By: 
Name: Silviu Itescu
Title: Director

By: 
Name: WVA Siva Kumar
Title: Director/secretary (delete as applicable)

MESOBLAST UK LIMITED

By: _____
Title: _____

MESOBLAST, INC.

By: _____
Title: President

MESOBLAST INTERNATIONAL SÀRL

By: _____
Title: _____

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

MESOBLAST LIMITED ACN 109 431 870

By: _____

Title: _____

MESOBLAST UK LIMITED

By: MICHAEL ANTHONY GIBSON

Title: Director

MESOBLAST, INC.

By: Silviu Itescu

Title: President

MESOBLAST INTERNATIONAL SARL

By: _____

Title: _____

[Signature Page to Intellectual Property Security Agreement (Oaktree/Mesoblast)]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:


MESOBLAST LIMITED ACN 109 431 870

By: _____
Title: _____

MESOBLAST UK LIMITED

By: _____
Title: _____

MESOBLAST INC



By: Silviu Itescu
Title: President

MESOBLAST INTERNATIONAL SÀRL

By: _____
Title: _____

[Signature Page to Intellectual Property Security Agreement (Oaktree/Mesoblast)]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

MESOBLAST LIMITED ACN 109 431 870

By: _____

Title: _____

MESOBLAST UK LIMITED

By: _____

Title: _____

MESOBLAST, INC.

By: Silviu Itescu

Title: President

MESOBLAST INTERNATIONAL SÀRL

By:  Chaltancin Ralph

Title: _____

[Signature Page to Intellectual Property Security Agreement (Oaktree/Mesoblast)]

EXHIBIT A

Copyrights and Exclusive Inbound Copyright Licenses

None.

EXHIBIT B

Patents

[See attached]

MESOMAST — Owned Patent Families

Patent Family Entitled:

Mesenchymal precursor cell

Country	Official Number	Patent Ref	Date Filed	Status
US	7122178	502997	07/07/2000	Registered
US	7670628	502998	29/03/2004	Registered
US	8158118	503361	29/06/2005	Registered
	divisional of 7122178			

Patent Family Entitled:

Perivascular mesenchymal precursor cells

Country	Official Number	Patent Ref	Date Filed	Status
AT	2380971	510675AT	24/03/2011	Registered
	validation of EP 2380971			
AU	2004223798	503826	29/03/2004	Registered
AU	2009227897	508714	21/10/2009	Registered
	divisional of 2006203627			
BE	2380971	510675BE	24/03/2011	Registered
	validation of EP 2380971			
CA	2520273	503827	29/03/2004	Registered
CA	2816489	513376	29/03/2004	Under Examination
	divisional of 2520273			
CH	2380971	510675CH	24/03/2011	Registered
	validation of EP 2380971			
CN	ZL200480014698.7	503831	29/03/2004	Registered
CN	ZL201310127300.1	513275	29/03/2004	Registered
	div of ZL200480014698.7			
DE	602004054514.7	510675DE	24/03/2011	Registered
	validation of EP 2380971			
EP	11159624.3	510675	24/03/2011	Registered
	divisional of 04723935.5			
ES	11159624.3	510675ES	24/03/2011	Registered
	validation of EP 2380971			
FI	2380971	510675FI	24/03/2011	Registered
	validation of EP 2380971			
FR	2380971	510675FR	24/03/2011	Registered
	validation of EP 2380971			
GB	2380971	510675GB	24/03/2011	Registered

MESOMAST — Owned Patent Families

Country	Official Number	EP Ref	Date Filed	Status
	validation of EP 2380971			
IE	2380971	510675IE	24/03/2011	Registered
	validation of EP 2380971			
IT	2380971	510675IT	24/03/2011	Awaiting Filing
	validation of EP 2380971			
JP	6043469	510270	09/12/2010	Registered
	divisional of 2006-503989			
JP	6188435	513682	11/06/2013	Registered
	divisional of 2010-274732			
JP	6257559	517331	02/06/2015	Registered
	divisional of 2010-274732			
NL	2380971	510675NL	24/03/2011	Registered
	validation of EP 2380971			
SK	2380971	510675SK	24/03/2011	Awaiting Filing
	validation of EP 2380971			
TR	2020/03912	510675TR	24/03/2011	Registered
	validation of EP 2380971			
US	7947266	503832	29/03/2004	Registered
	continuation of 13/098892			
US	10,421,946	517444	23/06/2015	Registered

Patent Family Entitled:

Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPCs)

Country	Official Number	EP Ref	Date Filed	Status
AU	2005287855	505306	29/06/2005	Registered
AU	2011224061	511261	15/09/2011	Registered
	divisional of 2005287855			
BE	1807505	505309BE	29/06/2005	Registered
	validation of EP1807505			
CA	2581237	505307	29/06/2005	Registered
CH	1807505	505309CH	29/06/2005	Registered
	validation of EP1807505			
CN	ZL200580039970.1	505308	29/06/2005	Registered
CN	ZL201210295857.1	512449	29/06/2005	Registered
	divisional of 200580039970.1			
DE	1807505	505309DE	29/06/2005	Registered
	validation of EP1807505			

NEOSOLAST — Owned Patent Families

Country	Official Number	Patent Ref	Date Filed	Status
EP	1807505	505309	29/06/2005	Registered
ES	1807505 validation of EP1807505	505309ES	29/06/2005	Registered
FR	1807505 validation of EP1807505	505309FR	29/06/2005	Registered
GB	1807505 validation of EP1807505	505309GB	29/06/2005	Registered
IE	1807505 validation of EP1807505	505309IE	29/06/2005	Registered
IT	1807505 validation of EP1807505	505309IT	29/06/2005	Registered
JP	5753545 divisional of 2007-532722	513052	17/01/2013	Registered
KR	10-1598947 div of 10-2013-7022534	516466	17/02/2015	Registered
NL	1807505 validation of EP1807505	505309NL	29/06/2005	Registered
TR	2017/16418 validation of EP1807505	505309TR	29/06/2005	Registered
US	10,544,394 continuation of 12/924008	515709	27/08/2014	Registered

Patent Family Entitled:

Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase

Country	Official Number	Patent Ref	Date Filed	Status
AU	2006235211	506289	12/04/2006	Registered
AU	2016200809 divisional of 2013202303	519940	09/02/2016	Registered
AU	2020201937 divisional of 2017272192	526853AU01	18/03/2020	Allowed
BE	2399991 validation of EP2399991	509951BE	08/03/2011	Registered
CA	2604493	506292	12/04/2006	Registered
CH/LI	1869165	506291CH	12/04/2006	Registered
CH/LI	2399991 validation of EP2399991	509951CH	08/03/2011	Registered
CN	ZL200680020870.9	506294	12/04/2006	Registered
DE	1869165	506291DE	12/04/2006	Registered

NEOSOLAST — Owner Patent Services

Country	Official Number	EPRIK Ref	Date Filed	Status
DE	2399991 validation of EP2399991	509951DE	08/03/2011	Registered
DK	1869165	506291DK	12/04/2006	Registered
EP	1869165	506291	12/04/2006	Registered
EP	2399991 divisional of 06721376.9	509951	08/03/2011	Registered
ES	2399991 validation of EP2399991	509951ES	08/03/2011	Registered
FR	1869165	506291FR	12/04/2006	Registered
FR	2399991 validation of EP2399991	509951FR	08/03/2011	Registered
GB	1869165	506291GB	12/04/2006	Registered
GB	2399991 validation of EP2399991	509951GB	08/03/2011	Registered
HK	09100738.8 validation of CN200680020870.9	507728	12/04/2005	Registered
IE	1869165	506291IE	12/04/2006	Registered
IE	2399991 validation of EP2399991	509951IE	08/03/2011	Registered
IN	278721	506296	12/04/2006	Registered
IT	1869165	506291IT	12/04/2006	Registered
IT	2399991 validation of EP2399991	509951IT	08/03/2011	Registered
JP	5462483	506293	12/04/2006	Registered
JP	5972851 divisional of 5462483	514607	26/11/2013	Registered
KR	10-1446634	506295	12/04/2006	Registered
KR	10-1617319 div. of 10-2007-7026272	515357	23/06/2014	Registered
KR	10-1682046 div. of 10-2014-7017212	520791	25/04/2016	Registered
NL	1869165	506291NL	12/04/2006	Registered
NL	2399991 validation of EP2399991	509951NL	08/03/2011	Registered
TR	2017/21532 validation of EP2399991	509951TR	08/03/2011	Registered

MESOMAST — Owned Patent Families

Country	Official Number	Patent Ref	Date Filed	Status
US	8367405	506290	12/04/2006	Registered
US	9783617	521036	27/05/2016	Registered
	div of 14/621470			
US	16/867252	525312US01	05/05/2020	Under Examination
	continuation of 15/651469			

Patent Family Entitled:

Perivascular mesenchymal precursor cell induced blood vessel formation

Country	Official Number	Patent Ref	Date Filed	Status
AT	1613335	503835AT	29/03/2004	Registered
	validation of EP1613335			
AU	2004224830	503833	29/03/2004	Registered
AU	2009227881	508715	21/10/2009	Registered
	divisional of 2006203628			
AU	2011253681	511473	24/11/2011	Registered
	divisional of 2009227881			
BE	1613335	503835BE	29/03/2004	Registered
	validation of EP1613335			
BE	2380969	510585BE	22/02/2011	Registered
	validation of EP2380969			
CA	2520390	503834	29/03/2004	Registered
CH	1613335	503835CH	29/03/2004	Registered
	validation of EP1613335			
CN	ZL200480014738.8	503838	29/03/2004	Registered
CZ	1613335	503835CZ	29/03/2004	Registered
	validation of EP1613335			
DE	602004044377.8	503835DE	29/03/2004	Registered
	validation of EP1613335			
DE	602004052910.9	510585DE	22/02/2011	Registered
	validation of EP2380969			
DK	1613335	503835DK	29/03/2004	Registered
	validation of EP1613335			
EP	1613335	503835	29/03/2004	Registered
EP	2380969	510585	22/02/2011	Registered
	divisional of 1613335			

NEOSOLAST — Owner Patent Services

Country	Official Number	Patent Ref	Date Filed	Status
ES	2465226 validation of EP1613335	503835ES	29/03/2004	Registered
ES	300290006 validation of EP2380969	510585ES	22/02/2011	Registered
FI	1613335 validation of EP1613335	503835FI	29/03/2004	Registered
FR	1613335 validation of EP1613335	503835FR	29/03/2004	Registered
FR	2380969 validation of EP2380969	510585FR	22/02/2011	Registered
GB	1613335 validation of EP1613335	503835GB	29/03/2004	Registered
GB	2380969 validation of EP2380969	510585GB	22/02/2011	Registered
HU	1613335 validation of EP1613335	503835HU	29/03/2004	Registered
IE	1613335 validation of EP1613335	503835IE	29/03/2004	Registered
IE	2380969 validation of EP2380969	510585IE	22/02/2011	Registered
IT	1613335 validation of EP1613335	503835IT	29/03/2004	Registered
IT	502018000029485 validation of EP2380969	510585IT	22/02/2011	Registered
JP	5721302	503837	29/03/2004	Registered
JP	6096082 divisional of 2006-503990	513996	16/08/2013	Registered
JP	6096232 divisional of 2013-169111	516723	09/03/2015	Registered
MC	1613335 validation of EP1613335	503835MC	29/03/2004	Registered
NL	1613335 validation of EP1613335	503835NL	29/03/2004	Registered
NL	2380969 validation of EP2380969	510585NL	22/02/2011	Registered
PL	1613335 validation of EP1613335	503835PL	29/03/2004	Registered
PT	1613335 validation of EP1613335	503835PT	29/03/2004	Registered
SI	1613335 validation of EP1613335	503835SI	29/03/2004	Registered

MESOMAST — Owned Patent Families

Country	Official Number	Patent Ref	Date Filed	Status
SE	1613335 validation of EP1613335	503835SE	29/03/2004	Registered
TR	201405181 validation of EP1613335	503835TR	29/03/2004	Registered
TR	2018/14365 validation of EP2380969	510585TR	22/02/2011	Registered
US	9169466	503839	29/03/2004	Registered
US	9175267 divisional of 9169466	503880	05/01/2006	Registered

Patent Family Entitled:

Multipotential expanded mesenchymal precursor cell progeny (MEMP) and uses thereof

Country	Official Number	Patent Ref	Date Filed	Status
AU	2005287872	505313	26/09/2005	Registered
BE	2348105 divisional of 05787106.3	510008BE	28/09/2010	Registered
CA	2866468 divisional of 2580975	514091	26/09/2005	Registered
CH	2348105 divisional of 05787106.3	510008CH	28/09/2010	Registered
CN	ZL200580040212.1	505315	26/09/2005	Registered
CN	ZL2011103490757 divisional of ZL200580040212.1	511395	26/09/2005	Registered
DE	2348105 divisional of 05787106.3	510008DE	28/09/2010	Registered
EP	2348105 divisional of 05787106.3	510008	28/09/2010	Registered
ES	2348105 divisional of 05787106.3	510008ES	28/09/2010	Registered
FR	2348105 divisional of 05787106.3	510008FR	28/09/2010	Registered
GB	2348105 divisional of 05787106.3	510008GB	28/09/2010	Registered
IE	2348105 divisional of 05787106.3	510008IE	28/09/2010	Registered
IT	2348105 divisional of 05787106.3	510008IT	28/09/2010	Registered
JP	5265190	505317	26/09/2005	Registered

NEOSOLAST — Owner Patent Families

Country	Official Number	Patent Ref	Date Filed	Status
JP	5927080 divisional of 5265190	512434	14/08/2012	Registered
KR	10-1441026	505318	26/09/2005	Registered
KR	10-1536613 divisional of 10-2007-7009300	514971	21/02/2014	Registered
NL	2348105 divisional of 05787106.3	510008NL	28/09/2010	Registered
TR	2348105 divisional of 05787106.3	510008TR	28/09/2010	Registered
US	17/369147 Continuation of 16/284878	527053US02	07/07/2021	Under Examination

Patent Family Entitled:

Treatment of excessive neovascularization

Country	Official Number	Patent Ref	Date Filed	Status
AU	2007272313	507702	12/07/2007	Registered
CA	2657308	507701	12/07/2007	Registered
CH/LI	2046349 validation of EP2046349	507700CH	12/07/2007	Registered
CN	ZL200780026432.8	507696	12/07/2007	Registered
DE	602007043024.0 validation of EP2046349	507700DE	12/07/2007	Registered
DK	2046349 validation of EP2046349	507700DK	12/07/2007	Registered
EP	2046349	507700	12/07/2007	Registered
FR	2046349 validation of EP2046349	507700FR	12/07/2007	Registered
GB	2046349 validation of EP2046349	507700GB	12/07/2007	Registered
HK	1129600 validation of EP2046349	508644	12/07/2007	Registered
IE	2046349 validation of EP2046349	507700IE	12/07/2007	Registered
IT	2046349 validation of EP2046349	507700IT	12/07/2007	Registered
JP	6041456	507697	12/07/2007	Registered

MEOSOLAST — Owned Patent Families

Country	Official Number	Patent Ref	Date Filed	Status
KR	10-1475303	507695	12/07/2007	Registered
NL	2046349 validation of EP2046349	507700NL	12/07/2007	Registered
SG	149206	507694	12/07/2007	Registered
US	15/788438 continuation of 12/309158	526562	19/10/2017	Under Examination

Patent Family Entitled:

Methods of generating, repairing and/or maintaining connective tissue *in vivo*

Country	Official Number	Patent Ref	Date Filed	Status
AU	2008286244	508943	06/08/2008	Registered
AU	2013203054 divisional of 2008286244	513351	06/08/2008	Registered
BE	2185165 validation of EP2185165	508946BE	06/08/2008	Registered
CA	2694107	508944	06/08/2008	Registered
CH	2185165 validation of EP2185165	508946CH	06/08/2008	Registered
CN	ZL200880102304.1	508945	06/08/2008	Registered
DE	2185165 validation of EP2185165	508946DE	06/08/2008	Registered
EP	2185165	508946	06/08/2008	Registered
EP	18190654.6 div of 2185165	508946EP01	24/08/2018	Under Examination
ES	2185165 validation of EP2185165	508946ES	06/08/2008	Registered
FR	2185165 validation of EP2185165	508946FR	06/08/2008	Registered
GB	2185165 validation of EP2185165	508946GB	06/08/2008	Registered
HK	19119390.3 validation of EP2185165	508946HK	13/02/2019	Filed
IE	2185165 validation of EP2185165	508946IE	06/08/2008	Registered
IT	2185165 validation of EP2185165	508946IT	06/08/2008	Registered
JP	6062615	508947	06/08/2008	Registered
JP	6505063 divisional of 2014-129035	520501	13/10/2016	Registered

NEOSOLAST — Owner Patent Families

Country	Official Number	Series Ref	Date Filed	Status
KR	10-1688449	518619	19/11/2015	Registered
	divisional of 10-2015-700235			
KR	10-2099285	525372KR01	27/06/2018	Registered
	divisional of 10-2017-7010476			
KR	10-2167440	525372KR02	29/11/2019	Registered
	divisional of 10-2099285			
NL	2185165	508946NL	06/08/2008	Registered
	validation of EP2185165			
SG	183694	512423	06/08/2008	Registered
	divisional of 201000194-9			
TR	2018/21239	508946TR	06/08/2008	Registered
	validation of EP2185165			
TW	1603736	507255	06/08/2008	Registered
US	9381216	508950	06/08/2008	Registered
US	16/585911	520956US01	27/09/2019	Under Examination
	continuation of 15/177708			

Patent Family Entitled:

Repair and/or reconstitution of intertebral discs

Country	Official Number	Series Ref	Date Filed	Status
AU	2009262358	510248	25/06/2009	Registered
AU	2017200689	524791	02/02/2017	Registered
	divisional of 2015202378			
BE	2303290	510250BE	25/06/2009	Registered
	validation of EP2303290			
BE	3378483	510250BE01	25/06/2009	Registered
	validation of EP3378483			
CA	2728102	510249	25/06/2009	Registered
CH	2303290	510250CH	25/06/2009	Registered
	validation of EP2303290			
CH	3378483	510250CH01	25/06/2009	Registered
	validation of EP3378483			
CN	ZL200980124157.2	510252	25/06/2009	Registered
CN	ZL201510405343.0	517583	10/07/2015	Registered
	div of 200980124157.2			
DE	602009053464.5	510250DE	25/06/2009	Registered
	validation of EP2303290			

NEOSOLAST — Owned Patent Services

COUNTRY	OFFICIAL NUMBER	SERIES REF	DATE FILED	STATUS
DE	602009063538.7 validation of EP3378483	510250DE01	25/06/2009	Registered
EP	2303290	510250	25/06/2009	Registered
EP	3378483 divisional of 2303290	510250EP01	01/05/2018	Registered
ES	300292838 validation of EP2303290	510250ES	25/06/2009	Registered
ES	300407815 validation of EP3378483	510250ES01	25/06/2009	Registered
FR	2303290 validation of EP2303290	510250FR	25/06/2009	Registered
FR	3378483 validation of EP3378483	510250FR01	25/06/2009	Registered
GB	2303290 validation of EP2303290	510250GB	25/06/2009	Registered
GB	3378483 validation of EP3378483	510250GB01	25/06/2009	Registered
HK	1217179 validation of CN201510405343.0	518469	06/05/2016	Registered
IE	2303290 validation of EP2303290	510250IE	25/06/2009	Registered
IE	378483 validation of EP3378483	510250IE01	25/06/2009	Registered
IT	502018000032110 validation of EP2303290	510250IT	25/06/2009	Registered
IT	502021000038765 validation of EP3378483	510250IT01	25/06/2009	Registered
JP	5801716	510251	25/06/2009	Registered
JP	6058729 divisional of 5801716	516672	08/04/2015	Registered
JP	6745713 divisional of 6058729	524300	06/12/2016	Registered
JP	2018-150268 divisional of 2016-236490	524300JP01	09/08/2018	Under Examination
JP	2020-92260 divisional of 2018-150268	524300JP02	27/05/2020	Under Examination
KR	10-1776959	510253	25/06/2009	Registered
NL	2303290 validation of EP2303290	510250NL	25/06/2009	Registered

NEOSOLAST — Owned Patent Families

Country	Official Number	Series Ref	Date Filed	Status
NL	378483 validation of EP3378483	510250N101	25/06/2009	Registered
SG	167191	510254	25/06/2009	Registered
SG	10201507149R divisional of 167191	518023	07/09/2015	Under Examination
TR	2018/15802 validation of EP2303290	510250TR	25/06/2009	Registered
TR	2021/007500 validation of EP3378483	510250TR01	25/06/2009	Registered
US	8858932	510255	25/06/2009	Registered
US	14/504308 continuation of 8858932	515585	01/10/2014	Under Examination

Patent Family Entitled:

Expansion of haemopoietic precursors

Country	Official Number	Series Ref	Date Filed	Status
AU	2009290134	510434	03/09/2009	Registered
AU	2016204920 div. of 2009290134	520957	14/07/2016	Registered
CA	2735800	510435	03/09/2009	Registered
CN	ZL200980134570.7	510438	03/09/2009	Registered
DE	602009041999.4 validation of EP09810917.6	510436DE	03/09/2009	Registered
EP	2324109	510436	03/09/2009	Registered
FR	23324109 validation of EP09810917.6	510436FR	03/09/2009	Registered
GB	23324109 validation of EP09810917.6	510436GB	03/09/2009	Registered
IT	23324109 validation of EP09810917.6	510436IT	03/09/2009	Registered
JP	5639058	510437	03/09/2009	Registered
KR	10-1708067	510439	03/09/2009	Registered
SG	193888 divisional of 201101360-4	513990	03/09/2009	Registered
US	8828375	510441	03/09/2009	Registered
US	9415072 continuation of 8828375	515586	03/09/2014	Registered

NEOSOLAST — Owned Patent Families

Patent Family Entitled:

Monoclonal antibody STRO-4

Country	Official Number	Patent Ref	Date Filed	Status
AU	2009284692	510459	18/08/2009	Registered
BE	2324359 Validation of EP2324359	510462BE	18/08/2009	Registered
CA	2734210	510460	18/08/2009	Registered
CH	2324359 Validation of EP2324359	510462CH	18/08/2009	Registered
CN	ZL200980141163.9	510461	18/08/2009	Registered
CN	ZL201510067688.X div. of ZL200980141163.9	516420	10/02/2015	Registered
CN	ZL201610940377.4 div. of ZL201510067688.X	523876	25/10/2016	Registered
DE	2324359 Validation of EP2324359	510462DE	18/08/2009	Registered
EP	2324359	510462	18/08/2009	Registered
ES	2324359 Validation of EP2324359	510462ES	18/08/2009	Registered
FR	2324359 Validation of EP2324359	510462FR	18/08/2009	Registered
GB	2324359 Validation of EP2324359	510462GB	18/08/2009	Registered
IE	2324359 Validation of EP2324359	510462IE	18/08/2009	Registered
IT	2324359 Validation of EP2324359	510462IT	18/08/2009	Registered
JP	5826629	510463	18/08/2009	Registered
KR	10-1713343	510464	18/08/2009	Registered
NL	2324359 Validation of EP2324359	510462NL	18/08/2009	Registered
SG	168850 10201601279S div. of 201100906-5	510465	18/08/2009	Registered
SG	10201601279S	520046	22/02/2016	Under Examination
TR	2324359 Validation of EP2324359	510462TR	18/08/2009	Registered
US	9090678	510466	18/08/2009	Registered
US	9815896	517601	09/07/2015	Registered

NEOSOLAST — Owned Patent Families

Country	Official Number	Office Ref	Date Filed	Status
	div of 9090678			

Patent Family Entitled:

Method for treating or preventing a pancreatic dysfunction

Country	Official Number	Office Ref	Date Filed	Status
AU	2009317874	510763	19/11/2009	Registered
BE	2350266 validation of EP2350266	510766BE	19/11/2009	Registered
BE	3002329 validation of EP3002329	517679BE	19/11/2009	Registered
CA	2744228	510764	19/11/2009	Registered
CH	2350266 validation of EP2350266	510766CH	19/11/2009	Registered
CN	ZL200980155054.2	510765	19/11/2009	Registered
CN	ZL201310652234.X div of ZL200980155054.2	514654	19/11/2009	Registered
CN	ZL201410727242.0 divisional of 201310652234.X	516101	03/12/2014	Registered
DE	2350266 validation of EP2350266	510766DE	19/11/2009	Registered
DE	602009047839.7 validation of EP3002329	517679DE	19/11/2009	Registered
DK	2350266 validation of EP2350266	510766DK	19/11/2009	Registered
EP	2350266	510766	19/11/2009	Registered
EP	3002329 divisional of 2350266	517679	19/11/2009	Registered
ES	2350266 validation of EP2350266	510766ES	19/11/2009	Registered
ES	2651503 validation of EP3002329	517679ES	19/11/2009	Registered
FR	2350266 validation of EP2350266	510766FR	19/11/2009	Registered
FR	3002329 validation of EP3002329	517679FR	19/11/2009	Registered
GB	2350266 validation of EP2350266	510766GB	19/11/2009	Registered
GB	3002329 validation of EP3002329	517679GB	19/11/2009	Registered
HK	14110752.1	515873	27/10/2014	Registered

NEOSOLAST — Owner Patent Services

Country	Official Number	Service Ref	Date Filed	Status
	validation of CN201310652234.X			
HK	1223396 validation of EP3002329	523872	05/10/2016	Registered
IE	2350266 validation of EP2350266	510766IE	19/11/2009	Registered
IE	3002329 validation of EP3002329	517679IE	19/11/2009	Registered
IT	502015000066483 validation of EP2350266	510766IT	19/11/2009	Registered
IT	502017000130140 validation of EP3002329	517679IT	19/11/2009	Registered
JP	5891034	510767	19/11/2009	Registered
JP	6499016 divisional of 5891034	517349	02/06/2015	Registered
JP	2019-162845 divisional of 2017-112578	525740JP01	06/09/2019	Under Examination
JP	TBA divisional of 2019-162845	525740JP02	TBA	Awaiting Filing
KR	10-1832497	510768	19/11/2009	Registered
KR	10-2011609 div of 10-1832497	527288	19/02/2018	Registered
NL	2350266 validation of EP2350266	510766NL	19/11/2009	Registered
NL	3002329 validation of EP3002329	517679NL	19/11/2009	Registered
SG	201103369.3	510769	19/11/2009	Registered
TR	2017/17869 validation of EP3002329	517679TR	19/11/2009	Registered
US	8894972	510770	19/11/2009	Registered
US	9480713 continuation of 8894972	515912	07/11/2014	Registered
US	9968640 continuation of 9480713	523787	27/10/2016	Registered

MESOMAST — Owned Patent Families

Patent Family Entitled: Production of reprogrammed pluripotent cells

Country	Official Number	Pub No	Date Filed	Status
AU	2010225469	511252	22/03/2010	Registered
BE	3293257 Validation of EP3293257	526499BE	16/10/2017	Awaiting Filing
CA	2755870	511253	22/03/2010	Registered
CH	3293257 Validation of EP3293257	526499CH	16/10/2017	Awaiting Filing
CN	ZL201080012939.X	511258	22/03/2010	Registered
DE	602010046054.1 validation of EP2408904	511255DE	22/03/2010	Registered
DE	3293257 validation of EP3293257	526499DE	16/10/2017	Awaiting filing
EP	2408904	511255	22/03/2010	Registered
EP	3293257 divisional of 2408904	526499	16/10/2017	Registered
ES	3293257 validation of EP3293257	526499ES	16/10/2017	Awaiting filing
FR	2408904 validation of EP2408904	511255FR	22/03/2010	Registered
FR	3293257 validation of EP3293257	526499FR	16/10/2017	Awaiting filing
GB	2408904 validation of EP2408904	511255GB	22/03/2010	Registered
GB	3293257 validation of EP3293257	526499GB	16/10/2017	Awaiting filing
HK	18111711.5 Validation of EP3293257	526499HK	12/09/2018	Filed
IE	2408904 validation of EP2408904	511255IE	22/03/2010	Registered
IE	3293257 validation of EP3293257	526499IE	16/10/2017	Awaiting filing
IT	2408904 validation of EP2408904	511255IT	22/03/2010	Registered
IT	3293257 validation of EP3293257	526499IT	16/10/2017	Awaiting filing
JP	2012-500009	511257	22/03/2010	Registered
JP	6603529 div of 2012-500009	518215	25/09/2015	Registered

NEOSOLAST — Owned Patent Families

Country	Official Number	Series Ref	Date Filed	Status
JP	6708617 div of 6603529	526875	08/12/2017	Registered
KR	10-1764437	511254	22/03/2010	Registered
NL	3293257 validation of EP3293257	526499NL	16/10/2017	Awaiting filing
SG	174426	511259	22/03/2010	Registered
SG	196328 divisional of 174426	514728	13/12/2013	Registered
TR	TBA validation of EP3293257	526499TR	16/10/2017	Awaiting filing
US	9487756	511260	22/03/2010	Registered
US	15/299088 continuation of 9487756	524075	20/10/2016	Under Examination

Patent Family Entitled:

Method of treating graft versus host disease

Country	Official Number	Series Ref	Date Filed	Status
AU	2011274254	512850	04/07/2011	Registered
AU	2020204056 div of 2018236748	520960AU02	18/06/2020	Under Examination
BE	2593114 validation of EP2593114	512852BE	09/04/2018	Registered
BE	3366298 div of EP3366298	527052BE	08/01/2018	Registered
CA	2803639	512851	04/07/2011	Accepted
CH	2593114 validation of EP2593114	512852CH	05/04/2018	Registered
CH	3366298 div of EP3366298	527052CH	08/01/2018	Registered
CN	ZL201180042201.2	512855	04/07/2011	Registered
CN	ZL201611201948.9 div of 201180042201.2	519015	23/12/2016	Registered
DE	602011044990.7 validation of EP2593114	512852DE	03/04/2018	Registered
DE	602011068320.9 div of EP3366298	527052DE	08/01/2018	Registered
EP	2593114	512852	04/07/2011	Registered
EP	3366298 div of 2593114	527052	08/01/2018	Registered

NEOSOLAST — Owner Patent Services

Country	Official Number	Series Ref	Date Filed	Status
ES	2665328 validation of EP2593114	512852ES	09/04/2018	Registered
ES	300386171 div of EP3366298	527052ES	08/01/2018	Registered
FR	2593114 validation of EP2593114	512852FR	04/04/2018	Registered
FR	3366298 div of EP3366298	527052FR	08/01/2018	Registered
GB	2593114 validation of EP2593114	512852GB	03/04/2018	Registered
GB	3366298 div of EP3366298	527052GB	08/01/2018	Registered
HK	17112615.1 validation of CN 201611201948.9	526812	29/11/2017	Filed
IE	2593114 validation of EP2593114	512852IE	06/04/2018	Registered
IE	3366298 div of EP3366298	527052IE	08/01/2018	Registered
IT	502018000011014 validation of EP2593114	512852IT	10/04/2018	Registered
IT	502020000105367 div of EP3366298	527052IT	08/01/2018	Registered
JP	6385674 div of 6385674	512854	04/07/2011	Registered
JP	6505148 div of 10-1871472	524287	23/02/2017	Registered
KR	10-1871472	512856	04/07/2011	Registered
KR	10-1987642 div of 10-1871472	512856KR01	19/06/2018	Registered
NL	2593114 validation of EP2593114	512852NL	06/04/2018	Registered
NL	3366298 div of EP3366298	527052NL	08/01/2018	Registered
SG	186243	512857	04/07/2011	Registered
TR	TR 201805074 T4 validation of EP2593114	512852TR	10/04/2018	Registered
TR	2020/17208 div of EP3366298	527052TR	08/01/2018	Registered
US	9301978	512858	04/07/2011	Registered
US	10105394 continuation of 9301978	519977	26/02/2016	Registered

NEOSOLAST — Owned Patent Families

Country	Official Number	Series Ref	Date Filed	Status
US	10849932 continuation of 10105394	519977US01	14/09/2018	Registered
US	17/077698 continuation of 10849932	519977US02	22/10/2020	Under Examination

Patent Family Entitled:

Methods of treating or preventing rheumatic disease

Country	Official Number	Series Ref	Date Filed	Status
AU	2012278925	513368	04/07/2012	Registered
AU	2016216639 div of 2012278925	520962	18/08/2016	Registered
BE	2729155 Validation of EP2729155	514536BE	04/07/2012	Registered
CA	2839341	514534	04/07/2012	Registered
CH	2729155 Validation of EP2729155	514536CH	04/07/2012	Registered
CN	201280042829.7	514535	04/07/2012	Under Examination
DE	602012065304.3 Validation of EP2729155	514536DE	04/07/2012	Registered
EP	2729155	514536	04/07/2012	Registered
EP	19205930.1 div of 2729155	514536EP01	29/10/2019	Under Examination
ES	300347176 Validation of EP2729155	514536ES	04/07/2012	Registered
FR	2729155 Validation of EP2729155	514536FR	04/07/2012	Registered
GB	2729155 Validation of EP2729155	514536GB	04/07/2012	Registered
HK	1196948 validation of EP12807117.2	515872	17/10/2014	Registered
IE	2729155 Validation of EP2729155	514536IE	04/07/2012	Registered
IT	502019000111052 Validation of EP2729155	514536IT	04/07/2012	Registered
JP	6227527	514538	04/07/2012	Registered
JP	6563999 div of 6227527	526482	10/10/2017	Registered
NL	2729155 Validation of EP2729155	514536NL	04/07/2012	Registered

MESOLAST — Owned Patent Families

Country	Official Number	Office Ref	Date Filed	Status
KR	10-1786862	514539	04/07/2012	Registered
SG	195170	514540	04/07/2012	Registered
TR	2019/20668	514536TR	04/07/2012	Registered
US	9265796	514541	04/07/2012	Registered
US	9974812	520853	11/01/2016	Registered
US	10,596,199	520853US01	17/04/2018	Registered
US	continuation of 9265796 continuation of 9974812			

Patent Family Entitled:

Method for treating obesity and/or metabolic syndrome

Country	Official Number	Office Ref	Date Filed	Status
AU	2016247132	524048	20/10/2016	Registered
BE	2709634	514360BE	18/05/2012	Registered
CA	2836488	514358	18/05/2012	Allowed
CH	2709634	514360CH	18/05/2012	Registered
CN	ZL201280021426.2	514359	18/05/2012	Registered
CN	201710711269.4	526201	18/08/2017	Allowed
DE	602012072253.3	514360DE	18/05/2012	Registered
EP	2709634	514360	18/05/2012	Registered
ES	300388471	514360ES	18/05/2012	Registered
FR	2709634	514360FR	18/05/2012	Registered
GB	2709634	514360GB	18/05/2012	Registered
HK	1.195.488	515691	02/09/2014	Registered
IE	2709634	514360IE	18/05/2012	Registered
IT	502020000115196	514360IT	18/05/2012	Registered
JP	6091492	514362	18/05/2012	Registered

MESOMAST — Owned Patent Families

Country	Official Number	Office Ref	Date Filed	Status
KR	10-1967492	514363	18/05/2012	Registered
NL	2709634 Validation of EP2709634	514360NL	18/05/2012	Registered
SG	194930	514364	18/05/2012	Registered
TR	2020/18837 Validation of EP2709634	514360TR	18/05/2012	Registered
US	9388385	514365	18/05/2012	Registered
US	10,159,696 div. of 9388385	520965	08/06/2016	Registered

Patent Family Entitled:

Methods of treating or preventing neurological diseases

Country	Official Number	Office Ref	Date Filed	Status
AU	2012262675	513370	04/06/2012	Registered
BE	2714057 Validation of EP2714057	514520BE	04/06/2012	Registered
CA	2837895	514518	04/06/2012	Registered
CH	2714057 Validation of EP2714057	514520CH	04/06/2012	Registered
CN	ZL201280033785.1	514519	04/06/2012	Registered
DE	602012065484.8 Validation of EP2714057	514520DE	04/06/2012	Registered
EP	2714057	514520	04/06/2012	Registered
ES	2714057 Validation of EP2714057	514520ES	04/06/2012	Registered
FR	2714057 Validation of EP2714057	514520FR	04/06/2012	Registered
GB	2714057 Validation of EP2714057	514520GB	04/06/2012	Registered
HK	1196541 Validation of EP12792873.7	515838	08/10/2014	Registered
IE	2714057 Validation of EP2714057	514520IE	04/06/2012	Registered
IT	502019000111043 Validation of EP2714057	514520IT	04/06/2012	Registered
JP	6184942	514523	04/06/2012	Registered
KR	10-2002090	514522	04/06/2012	Registered
NL	2714057	514520NL	04/06/2012	Registered

MESORIAS – Owner Patent Families

SG	Validation of EP2714057 195127	514524	04/06/2012	Registered
TR	2019/21536 Validation of EP2714057	514520TR	04/06/2012	Registered
US	10,206,951	514525	04/06/2012	Registered
US	17/177065 Continuation of 16/240344	514525US02	16/02/2021	Under Examination

Patent Family Entitled:

Method of treating the effects of stroke

Country	Official Number	Office Ref	Date filed	Status
AU	2012262679	513371	04/06/2012	Registered
BE	2714058 Validation of EP2714058	514527BE	04/06/2012	Registered
CA	2837898	514526	04/06/2012	Registered
CH	2714058 Validation of EP2714058	514527CH	04/06/2012	Registered
CN	202110054916.5 div of 20128003263.1	514530CN01	15/01/2021	Under Examination
DE	602012054918.1 Validation of EP2714058	514527DE	04/06/2012	Registered
EP	2714058	514527	04/06/2012	Registered
EP	18213454.4 div of EP 2714058	514527EP01	18/12/2018	Under Examination
ES	300311056 Validation of EP2714058	514527ES	04/06/2012	Registered
FR	2714058 Validation of EP2714058	514527FR	04/06/2012	Registered
GB	2714058 Validation of EP2714058	514527GB	04/06/2012	Registered
HK	1196540 validation of EP12793424.8	515837	08/10/2014	Registered
HK	19133822.7 Validation of EP18213454.4	514527HK	18/12/2019	Filed
IE	2714058 Validation of EP2714058	514527IE	04/06/2012	Registered
IT	2714058 Validation of EP2714058	514527IT	04/06/2012	Filed
JP	6265890	514529	04/06/2012	Registered

MESOBLAST — Owned Patent Families

KR	1920277	514531	04/06/2012	Registered
NL	2714058 Validation of EP2714058	514527NL	04/06/2012	Registered
SG	195128	514532	04/06/2012	Registered
TR	2019/03887 Validation of EP2714058	514527TR	04/06/2012	Registered
US	17/194855 continuation of 14/456534	515588US01	08/03/2021	Under Examination

Patent Family Entitled:

Methods for increasing osteoblastic function

Country	Official Number	Office Ref	Date filed	Status
AU	2012307086	513372	07/09/2012	Registered
BE	2753342 Validation of EP 2753342	514963BE	10/07/2018	Registered
CA	2847575	514962	07/09/2012	Registered
CH	2753342 Validation of EP 2753342	514963CH	10/07/2018	Registered
CN	ZL 201280043642.9	514966	07/09/2012	Registered
CN	201810437581.3 divisional of 201280043642.9	514966CN01	09/05/2018	Under Examination
DE	602012045148.3 Validation of EP 2753342	514963DE	10/07/2018	Registered
EP	2753342	514963	07/09/2012	Registered
ES	2676886 Validation of EP 2753342	514963ES	10/07/2018	Registered
FR	2753342 Validation of EP 2753342	514963FR	10/07/2018	Registered
GB	2753342 Validation of EP 2753342	514963GB	10/07/2018	Registered
HK	HK1197183 Validation of EP2753342	515874	27/10/2014	Registered
IE	2753342 Validation of EP 2753342	514963IE	10/07/2018	Registered
IT	502018000020605 Validation of EP 2753342	514963IT	10/07/2018	Registered
JP	6363950	514965	07/09/2012	Registered
JP	6444448 divisional of 6363950	525497	09/05/2017	Registered
KR	10-2009056	514967	07/09/2012	Registered

NEOSOLAST — Owned Patent Families

NL	2753342 validation of EP 2753342	514963NL	10/07/2018	Registered
SG	11201400218Y 2018/09635 validation of EP 2753342	514968 514963TR	07/09/2012 10/07/2018	Registered Registered
US	9642878	514969	07/09/2012	Registered
US	11135249 divisional of 15/485637	525324US01	02/07/2019	Registered

Patent Family Entitled:

Methods of treating or preventing respiratory conditions

Country	Official Number	Pub No	Date Filed	Status
AU	2013360026	517246	12/12/2013	Registered
AU	2018226514 div of 2013360026	517246AU01	14/09/2018	Registered
AU	2020202022 div of 2018226514	517246AU02	20/03/2020	Under Examination
BE	2931373 Validation of EP 2931373	517032BE	12/12/2013	Registered
CA	2893951	517247	12/12/2013	Under Examination
CH	2931373 Validation of EP 2931373	517032CH	12/12/2013	Registered
CN	201380072492.9	517248	12/12/2013	Under Examination
DE	602013059579.8 Validation of EP 2931373	517032DE	12/12/2013	Registered
EP	2931373	517032	12/12/2013	Registered
ES	300343709 Validation of EP 2931373	517032ES	12/12/2013	Registered
FR	2931373 Validation of EP 2931373	517032FR	12/12/2013	Registered
GB	2931373 Validation of EP 2931373	517032GB	12/12/2013	Registered
HK	1210077 validation of EP2931373	517254	29/10/2015	Registered
IE	2931373 Validation of EP 2931373	517032IE	12/12/2013	Registered
IT	502019000099876 Validation of EP 2931373	517032IT	12/12/2013	Registered
JP	6313327	517250	12/12/2013	Registered
JP	6665218	527461	22/03/2018	Registered

NEOSOLAST — Owned Patent Families

	divisional of 6313327			
JP	026138/2020 divisional of 6665218	527461JP01	19/02/2020	Under Examination
KR	10-1748712	517251	12/12/2013	Registered
NL	2931373 Validation of EP 2931373	517032NL	12/12/2013	Registered
SG	11201504352T	517252	12/12/2013	Registered
SG	10201807682P divisional of 11201504352T	517252SG01	06/09/2018	Under Examination
SG	10201807682P divisional of 11201504352T	517252SG01	06/09/2018	Under Examination
TR	2019/18140 Validation of EP 2931373	517032TR	12/12/2013	Registered
US	10,028,979	517253	12/12/2013	Registered
US	10,688,134 continuation of 10,028,979	517253US01	16/07/218	Registered
US	16/889354 continuation of 10,688,134	517253US02	01/06/2020	Under Examination

Patent Family Entitled:

Treatment of diseases of endothelial dysfunction and inflammation

Country	Official Number	Pub. No.	Date filed	Status
AU	2013360024	517255	12/12/2013	Registered
AU	2019202960 div of 2013360024	517255AU01	29/04/219	Allowed
AU	2021250848 div of 2019202960	517255AU02	29/04/2019	Filed
BE	2931876 Validation of EP 2931876	517033BE	12/12/2013	Registered
CA	2893942	517256	12/12/2013	Under Examination
CH	2931876 Validation of EP 2931876	517033CH	12/12/2013	Registered
CN	ZL201380072732.5	517257	12/12/2013	Registered
CN	202010796960.9 div of ZL201380072732.5	517257CN01	10/08/2020	Under Examination
DE	602013056083.8 Validation of EP 2931876	517033DE	12/12/2013	Registered
EP	2931876	517033	12/12/2013	Registered
EP	19174698.1 div of EP 2931876	517033EP01	12/12/2013	Under Examination

NEOSOLAST — Owner Patent Services

Country	Official Number	Service Ref	Date Filed	Status
ES	300330662 Validation of EP 2931876	517033ES	12/12/2013	Registered
FR	2931876 Validation of EP 2931876	517033FR	12/12/2013	Registered
GB	2931876 Validation of EP 2931876	517033GB	12/12/2013	Registered
HK	15110737.0 validation of EP13862555.3	517263	29/10/2015	Filed
HK	42020005251.2 Validation of EP19174698.1	517033HK	02/04/2020	Filed
IE	2931876 Validation of EP 2931876	517033IE	12/12/2013	Registered
IT	502019000067956 Validation of EP 2931876	517033IT	12/12/2013	Registered
JP	657213	517259	12/12/2013	Registered
JP	6829288 div. of 6572130	517259JP01	01/07/2019	Registered
JP	2021-008250 div. of 6829288	517259JP02	21/01/2021	Under Examination
KR	10-2217962	517260	12/12/2013	Registered
KR	10-2021-7004422 Div. of 10-2217962	517260KR01	15/02/2021	Under Examination
NL	2931876 Validation of EP 2931876	517033NL	12/12/2013	Registered
SG	11201504340Y	517261	12/12/2013	Registered
SG	10201705061R div. of 11201504340Y	525791	20/06/2017	Under Examination
TR	2019/12192 Validation of EP 2931876	517033TR	12/12/2013	Registered
US	14/650172	517262	12/12/2013	Under Examination

MECOMAST – Owned Patent Families

Patent Family Entitled:

Improved stem cell composition

Country	Official Number	Office Ref	Date Filed	Status
AU	2015243575	523752	07/04/2015	Registered
AU	2018200619	527084	25/01/2018	Registered
AU	2020202214	527084AU01	02/04/2020	Under Examination
CA	2944262	523753	07/04/2015	Under Examination
CN	ZL201580018440.2	523754	07/04/2015	Registered
CN	202110474002.4	523754CN01	29/04/2021	Under Examination
EP	15741940.9	523755	07/04/2015	Under Examination
HK	17101701.9	523756	07/04/2015	Filed
JP	6882161	523757	07/04/2015	Registered
JP	2021-24189	523757JP01	18/04/2021	Under Examination
KR	10-2016-7031018	523758	07/04/2015	Under Examination
SG	112016079255	523759	07/04/2015	Registered
SG	10202000644T	523759SG01	22/01/2020	Under Examination
US	10,400,218	523760	07/04/2015	Registered
US	16/434726	523760US01	07/06/2019	Under Examination

Patent Family Entitled:

Treatment of immune disorders

Country	Official Number	Office Ref	Date Filed	Status
AU	2015273799	524265	28/11/2016	Registered
AU	2020244403	524265AU0	28/09/2020	Under Examination
CA	2950804	524266	30/11/2016	Under Examination
CN	201580030754.4	524267	09/12/2016	Under Examination
CN	TBA	524267/CN01	TBA	TBA

MESOMAST — Owned Patent Families

EP	15728457.1	524268	23/12/2016	Under Examination
HK	17105054.3 validation of EP15728457.1	525586	19/05/2017	Filed
JP	6800757	524269	09/12/2016	Registered
JP	2020-195123 div. of 6800757	524269JP01	25/11/2020	Under Examination
KR	10-2017-7000032	524270	02/01/2017	Under Examination
SG	11201609993Y	524271	28/11/2016	Registered
US	10,624,930	524272	09/12/2016	Registered
US	16/828121 Continuation of 10,624,930	524272US01	24/03/2020	Under Examination

Patent Family Entitled:

Method for treating heart failure

Country	Official Number	Patent Ref	Date Filed	Status
AU	2015371007	525657	06/06/2017	Allowed
AU	202124010 Div. of 2015371007	525657AU01	06/06/2017	Filed
BR	1120170129116	525784	15/06/2017	Registered
CA	2971512	525658	19/06/2017	Under Examination
CN	201580076679.5	525659	22/08/2017	Under Examination
EP	15820153.3	525660	12/06/2017	Allowed
HK	17111250.3 validation of EP15820153.3	525661	02/11/2017	Filed
JP	6804451	525662	22/06/2017	Registered
JP	2020-199440 div. of 6804451	525662JP01	01/12/2020	Under Examination
KR	10-2017-7018961	525663	07/07/2017	Under Examination
SG	11201704780U	525664	09/06/2017	Registered
SG	10202008024V div. of 11201704780U	525664SG01	20/08/2020	Filed
US	15/534371	525665	08/06/2017	Under Examination

MESOMAST – Owned Patent Families

Patent Family Entitled:

Prevention of progressive heart failure

Country	Official Number	Patent Ref	Date Filed	Status
AU	2015371011	525590	06/06/2017	Registered
AU	2021240329 div of 2015371011	525590AU01	06/06/2017	Filed
BR	1120170129124	525785	15/06/2017	Under Examination
CA	2971514	525591	19/06/2017	Under Examination
CN	201580070480.1	525592	23/06/2017	Under Examination
EP	15822938.5	525593	12/06/2017	Under Examination
HK	17111249.7 validation of EP15822938.5	525594	02/11/2017	Filed
JP	2017-533780	525595	22/06/2017	Under Examination
JP	TBA div of 2017-533780	525595JP01	TBA	TBA
KR	10-2017-7018960	525596	07/07/2017	Under Examination
SG	11201704781X	525597	09/06/2017	Registered
US	15/534376	525598	08/06/2017	Under Examination

Patent Family Entitled:

Cell culture method for mesenchymal stem cells

Country	Official Number	Patent Ref	Date Filed	Status
AU	2016227607	526179	17/08/2017	Allowed
AU	2021254538 div of 2016227607	526179AU01	19/10/2021	Filed
BR	1120170188856	526188	01/09/2017	Under Examination
CA	2977578	526180	23/08/2017	Under Examination
CN	201680025469.8	526181	02/11/2017	Under Examination
CN	202111251410.X div of 201680025469.8	526181CN01	27/10/2021	Under Examination
EP	16707810.4	526182	25/09/2017	Allowed
EP	21205011.6 div of EP3265554	526182EP01	TBA	Awaiting Filing
HK	18100370.0	526183	11/01/2018	Filed
JP	6885870	526184	01/09/2017	Registered
JP	2021-42409	526184JP01	16/03/2021	Filed

MESOMAST – Owned Patent Families

	div of 6885870		
KR	10-2017-7025840	526185	13/09/2017
SG	11201706886P	526186	23/08/2017
US	16/599271 <small>cont of 15/553115</small>	526187US01	11/10/2019

Patent Family Entitled:

Potency Assay

Country	Official Number	Office Ref	Date Filed	Status
AU	2016258980	526534	30/10/2017	Under Examination
BR	112017023660-5	526543	01/11/2017	Under Examination
CA	2984987	526535	03/11/2017	Under Examination
CN	201680030528.0	526536	27/11/2017	Under Examination
EP	16725775.7	526537	03/11/2017	Allowed
HK	18106390.3 <small>Validation of EP16725775.7</small>	526538	17/05/2018	Filed
JP	6797833	526539	02/11/2017	Registered
JP	2020-190850 <small>Div of 6797833</small>	526539JP01	17/11/2020	Under Examination
KR	10-2017-7034098	526540	24/11/2017	Under Examination
SG	11201708967X	526541	31/10/2017	Under Examination
US	15/571178	526542	01/11/2017	Under Examination

Patent Family Entitled:

Methods and apparatus for separating cells from microcarriers

Country	Official Number	Office Ref	Date Filed	Status
BE	3303549 <small>Validation of EP3303549</small>	526683BE	27/11/2017	Registered
CH	3303549 <small>Validation of EP3303549</small>	526683CH	27/11/2017	Registered
CN	201680031179.4	526682	29/11/2017	Under Examination
DE	602016021690.6 <small>Validation of EP3303549</small>	526683DE	27/11/2017	Registered
EP	3303549	526683	27/11/2017	Registered
ES	3303549 <small>Validation of EP3303549</small>	526683ES	27/11/2017	Registered
FR	3303549 <small>Validation of EP3303549</small>	526683FR	27/11/2017	Registered
GB	3303549	526683GB	27/11/2017	Registered

MESENCHYMAL — Owned Patent Families

	Validation of EP3303549		
HK	18109229.4 validation of CN 201680031179.4	526682HK	17/07/2018 Filed
IE	3303549 Validation of EP3303549	526683IE	27/11/2017 Registered
IT	502019000108076 Validation of EP3303549	526683IT	27/11/2017 Registered
JP	6858713	526684	28/11/2017 Registered
NL	3303549 Validation of EP3303549	526683NL	27/11/2017 Registered
TR	2019/20641 Validation of EP3303549	526683TR	27/11/2017 Registered
US	15/575160	526685	17/11/2017 Allowed

Patent Family Entitled:

Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Country	Official Number	Office Ref	Date Filed	Status
AU	2018262788	524851AU	04/05/2018	Filed
BR	1120190229019	524851BR	04/05/2018	Under Examination
CA	3062112	524851CA	04/05/2018	Filed
CN	201880036997.2	524851CN	04/05/2018	Under Examination
EP	18726345.4	524851EP	04/05/2018	Under Examination
HK	62020013579.1 Validation of EP18726345.4	524851HK	12/08/2020	Filed
IN	201917046423	524851IN	04/05/2018	Under Examination
JP	2019-560259	524851JP	04/05/2018	Under Examination
KR	10-2019-7035053	524851KR	04/05/2018	Under Examination
SG	11201909856X	524851SG	04/05/2018	Under Examination
US	16/607293	524851US	04/05/2018	Under Examination

Patent Family Entitled:

Cellular compositions and methods of treatment I

Country	Official Number	Office Ref	Date Filed	Status
AU	2018372631	526519AU	21/11/2018	Filed
BR	1120200100790	526519BR	21/11/2018	Filed
CA	3084575	526519CA	21/11/2018	Filed

MESOMAST — Owned Patent Families

Country	Official Number	Priority Ref	Date Filed	Status
CN	201880083837.3	526519CN	21/11/2018	Under Examination
EP	18830515.5	526519EP	21/11/2018	Under Examination
HK	62021024830.3	526519HK	21/11/2018	Filed
IN	202017020886	526519IN	21/11/2018	Filed
JP	2020-528166	526519JP	21/11/2018	Filed
KR	10-2020-7017952	526519KR	21/11/2018	Filed
SG	11202004680U	526519SG	21/11/2018	Under Examination
US	16/766206	526519US	21/11/2018	Filed

Patent Family Entitled:

Expansion of hematopoietic stem cells

Country	Official Number	Priority Ref	Date Filed	Status
AU	2019370723	529040AU	30/04/2021	Filed
BR	11.2021.008265.4	529040BR	30/04/2021	Filed
CA	3,117,459	529040CA	30/04/2021	Filed
CN	201980076363.4	529040CN	30/04/2021	Filed
EP	19798048.5	529040EP	30/04/2021	Filed
IN	202117022612	529040IN	30/04/2021	Filed
JP	TBA	529040JP	30/04/2021	Filed
KR	10-2021-7015791	529040KR	30/04/2021	Filed
SG	11202103901Y	529040SG	30/04/2021	Filed
US	17/286,972	529040US	30/04/2021	Filed

Patent Family Entitled:

Method for treating lower back pain

Country	Official Number	Priority Ref	Date Filed	Status
AU	2020204805	529377AU	02/07/2021	Filed
BR	11.2021.013158.2	529377BR	02/07/2021	Filed
CA	3125308	529377CA	02/07/2021	Filed
CN	202080007828.3	529377CN	02/07/2021	Filed
EP	20701503.3	529377EP	02/07/2021	Filed
IN	202117032995	529377IN	02/07/2021	Filed
JP	2021-538792	529377JP	02/07/2021	Filed
KR	10-2021-7022383	529377KR	02/07/2021	Filed

MESOMAST – Owned Patent Families

SG	11202106794W	529377SG	02/07/2021	Filed
US	17/420314	529377US	02/07/2021	Filed

Patent Family Entitled:

Method for improving visual acuity

Country	Official Number	Pub No	Date Filed	Status
AU	2020204809	529229AU	03/07/2021	Filed
BR	11 2021 012923 5	529229BR	03/07/2021	Filed
CA	3125309	529229CA	03/07/2021	Filed
CN	202080007819.4	529229CN	03/07/2021	Filed
EP	20701505.8	529229	03/07/2021	Filed
HK	TBA	529229	03/07/2021	Awaiting Filing
IN	202117032690	529229IN	03/07/2021	Filed
JP	2021-539033	529229JP	03/07/2021	Filed
KR	10-2021-7021202	529229KR	03/07/2021	Filed
SG	11202106795R	529229SG	03/07/2021	Filed
US	17/420325	529229US	03/07/2021	Filed

Patent Family Entitled:

Method for treating or preventing gastrointestinal bleeding

Country	Official Number	Pub No	Date Filed	Status
US	17/425893	529533US	28/01/2020	Filed

Applications

Patent Family Entitled:

Functional recovery from Cerebral Infarction

Country	Official Number	Pub No	Date Filed	Status	Next Action
PCT	PCT/EP2020/064271	530082PCT	22/05/2020	Filed	National Phase deadline: 23/11/2021

Patent Family Entitled:

Cellular compositions comprising viral vectors and methods of treatment

Country	Official Number	Pub No	Date Filed	Status	Next Action

MESOMIAST – Owned Patent Families

PCT	PCT/IB2020/057410	530670PCT	05/08/2020	Filed	National Phase deadline: 05/02/2022
-----	-------------------	-----------	------------	-------	--

Patent Family Entitled: Method for treating chronic graft versus host disease

Country	Official Number	Patent Ref	Date Filed	Status	Next Action
PCT	PCT/EP2021/054066	531685PCT	18/02/2021	Filed	National Phase deadline: 19/08/2022

Patent Family Entitled: Method for treating inflammatory lung diseases which comprise administering mesenchymal lineage precursor or stem cells

Country	Official Number	Patent Ref	Date Filed	Status	Next Action
PCT	PCT/EP2021/055483	531860PCT	05/03/2021	Filed	National Phase deadline: 05/09/2022

Patent Family Entitled: Method for treating inflammatory bowel disease I

Country	Official Number	Patent Ref	Date Filed	Status	Next Action
PCT	PCT/EP2021/056191	531747PCT	11/03/2021	Filed	National Phase deadline: 11/09/2022

Patent Family Entitled: Method for treating inflammatory bowel disease II
 Earliest Priority Date: 11 March 2020

Country	Official Number	Patent Ref	Date Filed	Status	Next Action
PCT	PCT/EP2021/056193	531754PCT	11/03/2021	Filed	National Phase deadline: 11/09/2022

Patent Family Entitled: Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells

Country	Official Number	Patent Ref	Date Filed	Status	Next Action
PCT	PCT/EP2021/058683	532065PCT	01/04/2021	Filed	National Phase deadline: 03/10/2022

Patent Family Entitled: 3D culture of mesenchymal lineage precursor or stem cells

Country	Official Number	Patent Ref	Date Filed	Status	Next Action

MESOMAST – Owned Patent Families

PCT	PCT/IB2021/055055	532435PCT	10/06/2021	Filed	National Phase deadline: 11/12/2022
-----	-------------------	-----------	------------	-------	--

Patent Family Entitled: Composition and method

Country	Official Number	Patent Ref	Date Filed	Status	Next Action
PCT	PCT/IB2021/057314	532549PCT	10/08/2021	Filed	National Phase deadline: 10/02/2023

Patent Family Entitled: Cellular compositions and methods of treatment

Country	Official Number	Patent Ref	Date Filed	Status	Next Action
PCT	PCT/IB2021/0573	532902PCT	10/08/2021	Filed	National Phase deadline: 10/02/2023

Country	Official Number	Title	Inventors	Patent Ref	Date Filed	Earliest Priority Date	Status
AU	2020904675 2021900059 2021902941 2021903365	Method of treating progressive heart failure in subjects with Class II heart failure		533714PRV 533850PRV 535372PRV 535692PRV	15/12/2020	15/12/2020	Filed
AU	2021900147 2021900250	Optoid sparring compositions and methods of using the same		533889PRV 533947PRV	22/01/2021	22/01/2021	Filed
AU	2021901214 2021902180	Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells		534502PRV 535090PRV	23/04/2021	23/04/2021	Filed
AU	2021903277	Method for treating viral infection with mesenchymal lineage precursor or stem cells		535624PRV	12/10/2021	12/10/2021	Filed

MESOBLAST – Owned Patent Families

MSC families

Patent Family 25 Entitled: Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Country	Official Number	Patent Ref	Stem Ref	Date Filed	Status
JP	4740452	514465	3944.01JP02	12/03/1999	Registered

Patent Family 45 Entitled: Mesenchymal stem cells and uses therefor

Country	Official Number	Patent Ref	Stem Ref	Date Filed	Status
AU	2009200019	514141	3944.019AU11	02/01/2009	Registered
AU	divisional of 2005227295				
AU	2012205269	514143	3944.019AU31	20/07/2012	Registered
AU	divisional of 2009200019				
AU	2017268656	526836	3944.019AU51	01/12/2017	Registered
AU	2020201636	526836AU01	3944.019AU61	05/03/2020	Under Examination
AU	Divisional of 2017268656				
BE	2298864	514168BE	3944.019BE71	15/03/2005	Registered
BE	validation of EP2298864				
BE	2298862	514166BE	3944.019BE51	15/03/2005	Registered
BE	Validation of EP2298862				
BE	2298861	514165BE	3944.019BE41	15/03/2005	Registered
BE	Validation of EP2298861				
BE	2824175	515483BE	3944.019BE91	17/06/2014	Registered
BE	validation of EP2824175				
BE	(Mesoblast Int. Sarl)				
BE	2824174	515480BE	3944.019BE81	17/06/2014	Registered
BE	divisional of 2298861				
CA	2564679	514144	3944.019CA01	15/03/2005	Registered
CA	(Mesoblast Int. Sarl)				
CA	2868733	519685	3944.019CA31	29/10/2014	Registered
CA	divisional of 2564679				
CA	2934682	518472	3944.019CA41	29/06/2016	Allowed
CA	divisional of 2868733				

NEOSOLAST — Owner Patent Services

Country	Official Number	Patent Ref	Storage Ref	Date Filed	Status
CA	TBA divisional of 2934682	518472CA01	TBA	TBA	Awaiting filing
CH	2298863 validation of EP2298863	514167CH	3944.019CH61	15/03/2005	Registered
CH	2824175 validation of EP2824175	515483CH	3944.019CH91	17/06/2014	Registered
CH	2824174 divisional of 2298861	515480CH	3944.019CH81	17/06/2014	Registered
DE	602005033984.1 validation of EP1727892	514145DE	3944.019DE01	15/03/2005	Registered
DE	602005047073.5 validation of EP2298863	514167DE	3944.019DE61	15/03/2005	Registered
DE	602005052893.8 validation of EP2298864	514168DE	3944.019DE71	15/03/2005	Registered
DE	602005052645.5 validation of EP2298862	514166DE	3944.019DE51	15/03/2005	Registered
DE	60 2005 052 736.2 Validation of EP2298861	514165DE	3944.019DE41	15/03/2005	Registered
DE	602005053172.6 validation of EP2824175	515483DE	3944.019DE91	17/06/2014	Registered
DE	2824174 divisional of 2298861	515480DE	3944.019DE81	17/06/2014	Registered
EP	1727892	514145	3944.019EP01	15/03/2005	Registered
EP	2298861 divisional of 1727892	514165	3944.019EP41	15/03/2005	Registered
EP	2298862 divisional of 1727892	514166	3944.019EP51	15/03/2005	Registered
EP	2298863 divisional of 1727892	514167	3944.019EP61	15/03/2005	Registered
EP	2298864 divisional of 1727892	514168	3944.019EP71	15/03/2005	Registered
EP	2824174 divisional of 2298861	515480	3944.019EP81	17/06/2014	Registered
EP	18205743.0 divisional of 14172800.6	515480EP01	3944.019EPA1	12/11/2018	Under Examination
EP	2824175 divisional of 10011223.4	515483	3944.019EP91	17/06/2014	Registered
ES	1727892	514145ES	3944.019ES01	15/03/2005	Registered
ES	300166904 validation of EP2298863	514167ES	3944.019ES61	15/03/2005	Registered
ES	2645018	514168ES	3944.019ES71	15/03/2005	Registered

NEOSOLAST — Owner Patent Services

Country	Official Number	Patent Ref	Storage Ref	Date Filed	Status
	validation of EP2298864				
ES	2643076	514166ES	3944.019ES51	15/03/2005	Registered
	Validation of EP2298862				
ES	2643030	514165ES	3944.019ES41	15/03/2005	Registered
	Validation of EP2298861				
ES	2657382	515483ES	3944.019ES91	17/06/2014	Registered
	validation of EP2824175				
ES	2824174	515480ES	3944.019ES81	17/06/2014	Registered
	divisional of 2298861				
FR	1727892	514145FR	3944.019FR01	15/03/2005	Registered
FR	2298863	514167FR	3944.019FR61	15/03/2005	Registered
	validation of EP2298863				
FR	2298864	514168FR	3944.019FR71	15/03/2005	Registered
	validation of EP2298864				
FR	2298862	514166FR	3944.019FR51	15/03/2005	Registered
	Validation of EP2298862				
FR	2298861	514165FR	3944.019FR41	15/03/2005	Registered
	Validation of EP2298861				
FR	2824175	515483FR	3944.019FR91	17/06/2014	Registered
	validation of EP2824175				
FR	2824174	515480FR	3944.019FR81	17/06/2014	Registered
	divisional of 2298861				
GB	1727892	514145GB	3944.019GB01	15/03/2005	Registered
GB	2298863	514167GB	3944.019GB61	15/03/2005	Registered
	validation of EP2298863				
GB	2298864	514168GB	3944.019GB71	15/03/2005	Registered
	validation of EP2298864				
GB	2298862	514166GB	3944.019GB51	15/03/2005	Registered
	Validation of EP2298862				
GB	2298861	514165GB	3944.019GB41	15/03/2005	Registered
	Validation of EP2298861				
GB	2824175	515483GB	3944.019GB91	17/06/2014	Registered
	validation of EP2824175				
GB	2824174	515480GB	3944.019GB81	17/06/2014	Registered
	divisional of 2298861				
HK	1205531	517488	3944.019HK81	17/06/2014	Registered
	Validation from EP 2824174				
HK	1205677	518462	3944.019HK91	17/06/2014	Registered
	Validation from EP14172807.1				
HK	19121951.8	515480HK	3944.019HK41	08/04/2019	Filed
	Validation of EP 18205743.0				

NEOSOLAST — Owner Patent Services

Country	Official Number	Patent Ref	Startup Ref	Date Filed	Status
IE	2298864 validation of EP2298864	514168IE	3944.019IE71	15/03/2005	Registered
IE	2298862 Validation of EP2298862	514166IE	3944.019IE51	15/03/2005	Registered
IE	2298861 Validation of EP2298861	514165IE	3944.019IE41	15/03/2005	Registered
IE	2824175 validation of EP2824175	515483IE	3944.019IE91	17/06/2014	Registered
IE	2824174 divisional of 2298861	515480IE	3944.019IE81	17/06/2014	Registered
IT	1727892	514145IT	3944.019IT01	15/03/2005	Registered
IT	2298863 validation of EP2298863	514167IT	3944.019IT61	15/03/2005	Registered
IT	502017000123782 validation of EP2298864	514168IT	3944.019IT71	15/03/2005	Registered
IT	502017000120465 Validation of EP2298862	514166IT	3944.019IT51	15/03/2005	Registered
IT	502017000121348 Validation of EP2298861	514165IT	3944.019IT41	15/03/2005	Registered
IT	502018000004812 validation of EP2824175	515483IT	3944.019IT91	17/06/2014	Registered
IT	2824174 divisional of 2298861	515480IT	3944.019IT81	17/06/2014	Registered
JP	6114500 divisional of 2007-505005	514188	3944.019JP31	15/03/2012	Registered
JP	5997237 divisional of 6114500	516333	3944.019JP61	15/03/2012	Registered
JP	6382360 divisional of 6114500	524288	3944.019JP41	13/01/2017	Registered
JP	675730 divisional of 6382360	525531	3944.019JP51	10/08/2017	Registered
JP	6757383 divisional of 2017-155229	525531JP01	3944.019JP81	09/10/2018	Registered
JP	2020-047240 divisional of 6757300	525531JP02	3944.019JP9	18/03/2020	Under Examination
JP	TBA divisional of 2020-047240	525531JP03	3944.019JP9	18/03/2020	Filed
LI	2298863 validation of EP2298863	514167LI	N/A	15/03/2005	Registered
NL	2298864	514168NL	3944.0515483	15/03/2005	Registered

MESOBLAST — Owner Patent Services

Country	Official Number	Patent Ref	Storage Ref	Date Filed	Status
	validation of EP2298864		19NL71		
NL	2298862	514166NL	3944.019NL51	15/03/2005	Registered
	Validation of EP2298862				
NL	2298861	514165NL	3944.019NL41	15/03/2005	Registered
	Validation of EP2298861				
NL	2824175	515483NL	3944.019NL91	17/06/2014	Registered
	validation of EP2824175				
NL	2824174	515480NL	3944.019NL81	17/06/2014	Registered
	divisional of 2298861				
TR	2017/16011	514168TR	3944.019TR71	15/03/2005	Registered
	validation of EP2298864				
TR	2017/15120	514166TR	3944.019TR51	15/03/2005	Registered
	Validation of EP2298862				
TR	2017/14864	514165TR	3944.019TR41	15/03/2005	Registered
	Validation of EP2298861				
TR	2018/01019	515483TR	3944.019TR91	17/06/2014	Registered
	validation of EP2824175 (Mesoblast Int. Sarl)				
TR	2824174	515480TR	3944.019TR81	17/06/2014	Registered
	divisional of 2298861				
US	9943547	514893	3944.019000E	22/11/2013	Registered
	continuation of 12/908119				
US	9694035	515481	3944.019000H	17/07/2014	Registered
	divisional of 9943547				
US	10,668,101	514892	3944.019000F	23/12/2013	Registered
	continuation of 13/222778				
US	10729727	514892US01	3944.019000J	29/11/2018	Registered
	continuation 10,668,101				
US	10,716,814	514892US02	3944.019000K	29/11/2018	Registered
	continuation 10,668,101				
US	16/214485	514892US03	3944.019000L	10/12/2018	Under Examination
	continuation 14/138577				
US	10,960,025	514892US04	3944.019000M	06/03/2020	Registered
	continuation 10,668,101				
US	10,828,334	514892US05	3944.019000N	11/03/2020	Registered
	continuation 10,668,101				

MESOMAST — Owned Patent Families

Patent Family 45 Entitled:

Mesenchymal stem cells and uses therefor

Country	Official Number	Patent Ref	Series Ref	Date Filed	Status
BR	PI0717150-1	514187	3944.019BR04	26/09/2007	Under Examination
KR	10-1577553	515650	3944.019KR24	10/04/2014	Registered
	divisional of 10-2008-7025390				
KR	10-2020-7030690	526724KR01	3944.019KR84	23/10/2020	Under Examination
	divisional of 10-2017-7033780				
KR	TBA	526724KR02	TBA	TBA	Awaiting Filing
	divisional of 10-2020-7030690				

Patent Family 45 Entitled:

Mesenchymal stem cells and uses therefor

Country	Official Number	Patent Ref	Series Ref	Date Filed	Status
BE	2123747	514162BE	3944.019BE15	21/03/2008	Registered
	validation of EP2123747				
BE	3095450	518470BE	3944.019EP	21/03/2008	Registered
	Validation of EP3095450		25		
BE	19204349.5	518470BE01	3944.019EP	21/10/2019	Filed
	divisional of EP19204349.5		35		
BR	PI0802241-0	514161	3944.019BR05	21/03/2008	Under Examination
CA	2637157	514155	3944.019CA05	21/03/2008	Allowed
CA	TBA	514155CA01	3944.019CA05	TBA	Awaiting Filing
	div. of 2637157				
CH	2123747	514162CH	3944.019CH15	21/03/2008	Registered
	validation of EP2123747				
CH	3095450	518470CH	3944.019EP	21/03/2008	Registered
	Validation of EP3095450		25		
CH	19204349.5	518470CH01	3944.019EP	21/10/2019	Filed
	divisional of EP19204349.5		35		
DE	602008044669.7	514162DE	3944.019DE15	21/03/2008	Registered
	validation of EP2123747				
DE	3095450	518470DE	3944.019EP	21/03/2008	Registered
	Validation of EP3095450		25		
DE	19204349.5	518470DE01	3944.019EP	21/10/2019	Filed
	divisional of EP19204349.5		35		

NEOSOLAST — Owner Patent Services

Country	Official Number	EPRI No.	SPAT No.	Date Filed	Status
DK	2123747 validation of EP2123747	514162DK	3944.019DK15	21/03/2008	Registered
EP	2123747 divisional of 08744188.7	514162	3944.019EP15	21/03/2008	Registered
EP	3095450 divisional of 2123747	518470	3944.019EP25	21/03/2008	Registered
EP	19204349.5 divisional of 3095450	518470EP01	3944.019EP 35	21/10/2019	Allowed
EP	21195085.2 Divisional of EP19204349.5	518470EP02	3944.019EP 35	21/10/2019	Filed
ES	2577703 validation of EP2123747	514162ES	3944.019ES15	21/03/2008	Registered
ES	3095450 Validation of EP3095450	518470ES	3944.019EP 25	21/03/2008	Registered
ES	19204349.5 divisional of EP19204349.5	518470ES01	3944.019EP 35	21/10/2019	Filed
FR	2123747 validation of EP2123747	514162FR	3944.019FR15	21/03/2008	Registered
FR	3095450 Validation of EP3095450	518470FR	3944.019EP 25	21/03/2008	Registered
FR	19204349.5 divisional of EP19204349.5	518470FR01	3944.019EP 35	21/10/2019	Filed
GB	2123747 validation of EP2123747	514162GB	3944.019GB15	21/03/2008	Registered
GB	3095450 Validation of EP3095450	518470GB	3944.019EP 25	21/03/2008	Registered
GB	19204349.5 divisional of EP19204349.5	518470GB01	3944.019EP 35	21/10/2019	Filed
HK	HK1136601 validation of EP2123747	514163	3944.019HK15	21/03/2008	Registered
HK	1229734 validation of EP 3095450	525072	3944.019HK25	10/04/2017	Registered
HK	42020015213.0 Validation of EP19204349.5	518470HK	3944.019HK35	31/08/2020	Filed
IE	2123747 validation of EP2123747	514162IE	3944.019IE15	21/03/2008	Registered
IE	3095450 Validation of EP3095450	518470IE	3944.019EP25	21/03/2008	Registered

MESOBLAST — Owned Patent Families

Country	Official Number	EPRI Ref	Seqno Ref	Date filed	Status
IE	19204349.5 divisional of EP19204349.5	518470IE01	3944.019EP35	21/10/2019	Filed
IT	2123747 validation of EP2123747	514162IT	3944.019IT15	21/03/2008	Registered
IT	3095450 Validation of EP3095450	518470IT	3944.019EP25	21/03/2008	Registered
IT	19204349.5 divisional of EP19204349.5	518470IT01	3944.019EP35	21/10/2019	Filed
JP	5961220 divisional of 2009-554770	515482	3944.019JP35	17/06/2014	Registered
KR	10-2019-7007767 div of 10-2016-7004407	518463KR01	3944.019KR 55	18/03/2019	Under Examination
NL	2123747 validation of EP2123747	514162NL	3944.019NL15	21/03/2008	Registered
NL	3095450 Validation of EP3095450	518470NL	3944.019EP25	21/03/2008	Registered
NL	19204349.5 divisional of EP19204349.5	518470NL01	3944.019EP35	21/10/2019	Filed
TR	2020/00435 Validation of EP3095450	518470TR	3944.019EP25	21/03/2008	Registered
TR	19204349.5 divisional of EP19204349.5	518470TR01	3944.019EP35	21/10/2019	Filed

Patent Family 47 Entitled:

Mesenchymal stem cells expressing TNF-alpha receptor

Country	Official Number	EPRI Ref	Seqno Ref	Date filed	Status
AU	2007208504	514237	3944.022AU01	05/01/2007	Registered
AU	2011202952 divisional of 2007208504	514246	3944.022AU11	20/06/2011	Registered
AU	2012216549 divisional of 2011202952	514247	3944.022AU21	30/08/2012	Registered
BR	PI0706529 (Mesoblast Int. Sarl)	514238	3944.022BR01	05/01/2007	Under Examination
BR	BR122019023761-1 divisional of PI0706529	514328BR01	3944.022BR11	11/11/2019	Under Examination
CA	2635915	514239	3944.022CA01	05/01/2007	Registered
CA	2893204 divisional of 2635915	517614	3944.022CA11	01/06/2015	Registered
CH	1971679	514240CH	3944.022CH01	05/01/2007	Registered
CH	2465922	514248CH	3944.022CH11	05/01/2007	Registered

NEOSOLAST — Owned Patent Families

Country	Official Number	Patent Ref	Series Ref	Date Filed	Status
	validation of EP2465922				
DE	602007029656.0	514240DE	3944.022DE01	05/01/2007	Registered
DE	602007055615.5	514248DE	3944.022DE11	05/01/2007	Registered
	validation of EP2465922				
EP	1971679	514240	3944.022EP01	05/01/2007	Registered
EP	2465922	514248	3944.022EP11	05/01/2007	Registered
	divisional of 1971679				
EP	17181392.6	525525	3944.022EP21	14/07/2017	Under Examination
	divisional of 2465922				
ES	2415855	514240ES	3944.022ES01	05/01/2007	Registered
FR	1971679	514240FR	3944.022FR01	05/01/2007	Registered
FR	2465922	514248FR	3944.022FR11	05/01/2007	Registered
	validation of EP2465922				
GB	1971679	514240GB	3944.022GB01	05/01/2007	Registered
GB	2465922	514248GB	3944.022GB11	05/01/2007	Registered
	validation of EP2465922				
HK	1151553	514249	3944.022HK01	05/01/2007	Registered
	validation of EP1971679				
HK	1166344	514250	3944.022HK11	17/03/2009	Registered
	divisional of 1151553				
HK	18110664.4	525525HK	3944.022HK21	20/08/2018	Filed
	Validation of EP17181392.6				
IE	2465922	514248IE	3944.022IE11	05/01/2007	Registered
	validation of EP2465922				
IT	1971679	514240IT	3944.022IT01	05/01/2007	Registered
IT	502018000032834	514248IT	3944.022IT11	05/01/2007	Registered
	validation of EP2465922				
MX	310095	514242	3944.022MX01	05/01/2007	Registered
MX	348735	514253	3944.022MX11	13/03/2013	Registered
	divisional of 310095				
US	8486695	514251	3944.0220004	22/02/2012	Registered
	continuation of 12/091391				
US	17/087124	525141US01	3944.0220009	02/11/2020	Under Examination
	continuation of 15/693754				
ZA	2008/05609	514244	3944.022ZA01	05/01/2007	Registered

MESOMAST — Owned Patent Families

Patent Family 48 Entitled:

Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Country	Official Number	EPRI Ref	Source Ref	Date Filed	Status
AR	090103159 (Osiris Therapeutics)	514221	3944.023AR01	18/08/2009	Under Examination
AR	TBA div of 090103159 (Osiris Therapeutics)	514221AR01	3944.023AR02	TBA	Awaiting Filing
AU	2009281809	514222	3944.023AU01	14/08/2009	Registered
AU	2015268673 div of 2009281809	518907	3944.023AU11	11/12/2015	Registered
BE	2318519	514225BE	3944.023BE01	14/08/2009	Registered
BR	PI0917993-3	514223	3944.023BR01	14/08/2009	Registered
BR	122020009181-9 Div of PI0917993-3	514223BR01	3944.023BR11	08/05/2020	Filed
CA	2733985	514224	3944.023CA01	14/08/2009	Registered
CH	2318519	514225CH	3944.023CH01	14/08/2009	Registered
DE	602009041596.4	514225DE	3944.023DE01	14/08/2009	Registered
DK	2318519	514225DK	3944.023DK01	14/08/2009	Registered
EP	2318519	514225	3944.023EP01	14/08/2009	Registered
EP	16189444.9 div of 09807366.1	524274	3944.023EP11	14/08/2009	Under Examination
ES	2318519	514225ES	3944.023ES01	14/08/2009	Registered
FR	2318519	514225FR	3944.023FR01	14/08/2009	Registered
GB	2318519	514225GB	3944.023GB01	14/08/2009	Registered
HK	17103605.2 validation of EP16189444.9	525155	3944.023HK11	10/04/2017	Filed
IE	2318519	514225IE	3944.023IE01	14/08/2009	Registered
IL	211214	514226	3944.023IL01	14/08/2009	Registered
IT	2318519	514225IT	3944.023IT01	14/08/2009	Registered
JP	6025329	514227	3944.023JP01	14/08/2009	Registered
JP	2020-072934 div of 2018-036415	527378JP01	3944.023JP22	15/04/2020	Under Examination
MX	321939	514228	3944.023MX01	14/08/2009	Registered
MX	362512 divisional of 321939	515927	3944.023MX11	14/07/2014	Registered
NL	2318519	514225NL	3944.023NL01	14/08/2009	Registered

MESOMAST — Owned Patent Families

Country	Official Number	Patent Ref	Stem Cell Ref	Date Filed	Status
NZ	591146	514229	3944.023NZ01	14/08/2009	Registered
NZ	602248	514231	3944.023NZ11	05/09/2012	Registered
US	8637004	514232	3944.0230001	14/08/2009	Registered
US	16/694382	525119US01	3944.0230003	25/11/2019	Under Examination
ZA	2011/01858	514230	3944.023ZA01	14/08/2009	Registered

Patent Family 52 Entitled:

Enhanced MSC preparations

Country	Official Number	Patent Ref	Stem Cell Ref	Date Filed	Status
EP	19209202.1	514211EP01	3944.024EP 12	14/11/2019	Under Examination
HK	42020015349.2	514211HK	3944.024HK12	03/09/2021	Filed
US	9828586	514891	3944.0240003	23/12/2013	Registered
US	9963678	516744	3944.0240004	19/03/2015	Registered
US	10550369	516744US01	3944.0240005	04/04/2018	Registered
US	16/725677	516744US02	3944.0240006	23/12/2019	Under Examination

Patent Family Entitled:

Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

Country	Official Number	Patent Ref	Stem Cell Ref	Date Filed	Status
US	9308277	514897	50591-004003	27/02/2011	Registered
US	10456451	518464	50591-004004	26/02/2016	Registered

Patent Family Entitled:

Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1

NEOSOLAST — Owned Patent Families

Country	Official Number	Patent Ref	Chem & EMB Ref	Date Filed	Status
AU	2012268078	99261	50591-007AU2	06/06/2012	Registered
CA	2838155	514900	50591-007CA2	06/06/2012	Registered
DE	60 2012 042 402.8 validation of EP2717894	514901DE	N/A	14/04/2018	Registered
EP	2717894	514901	50591-007EP2	06/06/2012	Registered
FR	2717894 validation of EP2717894	514901FR	N/A	14/04/2018	Registered
GB	2717894 validation of EP2717894	514901GB	TBA	14/04/2018	Registered
HK	1196944 validation of EP12796309.8	515928	50591-007HK2	16/10/2014	Registered
IT	2717894 validation of EP2717894	514901IT	N/A	14/04/2018	Registered
JP	6145089	514904	50591-007JP2	06/06/2012	Registered
US	10,662,234	514905	50591-007002	06/06/2012	Registered

EXHIBIT C

Trademarks

[See attached]

Mark	Country	Status	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date	Goods/Services
BEICELL	Australia	Registered	MESOBLAST LIMITED	1958613	09/28/2018	1958613	06/04/2019	(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells, preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded (042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to T-cell production, T-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants
BEICELL	China	Registered	MESOBLAST LIMITED	1465873	03/28/2019	1465873	03/28/2019	(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells, preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded (042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants
BEICELL	Hong Kong	Registered	MESOBLAST LIMITED	304873555	03/28/2019	304873555	02/12/2020	(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells, preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded (042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to T-cell production, T-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants

BEICELL
International
Bureau of the
World
Intellectual
Property
Organization
(WIPO)

MESOBLAST
LIMITED

1465873

03/28/2019

1465873

03/28/2019

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances, diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants.

MESOBLAST

Australia
Registered

MESOBLAST
LIMITED

1022910

09/30/2004

1022910

02/08/2007

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications excluding preparations and substances for embryonic stem cells; diagnostic preparations and reagents for medical purposes excluding preparations and reagents for embryonic stem cells; culture fluids, including cultures of micro-organisms for medical purposes; human tissue other than embryonic stem cells; animal tissue other than embryonic stem cells; human tissue and animal tissue other than embryonic stem cells for transplantation or implantation, medical and surgical purposes; human cells including stem cells other than embryonic stem cells; animal cells including stem cells other than embryonic stem cells; preparations for the treatment, tissue other than embryonic stem cells; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to T-cell production, T-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants; none of the aforementioned services relating to embryonic stem cells

MESOBLAST United States Registered MESOBLAST LIMITED 78/596,837 03/29/2005 3,393,731 03/04/2008

(005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications but not including preparations for embryonic stem cells; veterinary preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications but not including preparations for embryonic stem cells; biotechnology preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications but not including preparations for embryonic stem cells; medical preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications but not including preparations for embryonic stem cells; diagnostic preparations and reagents for medical purposes but not including preparations and reagents for embryonic stem cells; culture fluids, namely, cultures of micro-organisms for medical purposes but not including cultures for embryonic stem cells; human allograft tissue but not including embryonic stem cells; animal allograft tissue but not including embryonic stem cells; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes but not including embryonic stem cells; human cells including stem cells but not embryonic stem cells; animal cells including stem cells for medical or clinical use but not embryonic stem cells; pharmaceutical preparations for the treatment, reconstruction and repair of embryonic stem cells;

(042 - INTERNATIONAL) Scientific, medical research, clinical research, pharmaceutical research and development, advisory and consultancy services in the field of T-cell production, T-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants; none of the aforementioned services relating to embryonic stem cells

MESOBLAST United States Registered MESOBLAST LIMITED 86/008,550 07/12/2013 4,494,438 03/11/2014

(005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications but not including preparations for embryonic stem cells; veterinary preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications but not including preparations for embryonic stem cells; biotechnology preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications but not including preparations for embryonic stem cells; medical preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications but not including preparations for embryonic stem cells; diagnostic preparations and reagents for medical purposes but not including preparations and reagents for embryonic stem cells; culture fluids, namely, cultures of micro-organisms for medical purposes but not including cultures for embryonic stem cells; human allograft tissue but not including embryonic stem cells; animal allograft tissue but not including embryonic stem cells; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes but not including embryonic stem cells; human cells including stem cells for medical or clinical use but not embryonic stem cells; animal cells including stem cells for medical or clinical use but not embryonic stem cells; pharmaceutical preparations for the treatment, reconstruction and repair of tissue but not including preparations for embryonic stem cells;

(042 - INTERNATIONAL) Scientific, medical research, clinical research, pharmaceutical research and development, advisory and consultancy services in the field of T-cell production, T-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants; none of the aforementioned services relating to embryonic stem cells

MESOVET	Australia	Registered	MESOBLAST LIMITED	1449656	09/21/2011	1449656	05/10/2012	(005 - INTERNATIONAL) Veterinary preparations and substances for the prevention, management, diagnosis and treatment of companion animals and livestock; diagnostic preparations and reagents for veterinary purposes; culture fluids, including cultures of micro-organisms for veterinary purposes; animal tissue; animal tissue for transplantation or implantation, veterinary purposes; animal cells including stem cells.
NEOFUSE	Australia	Registered	MESOBLAST LIMITED	1189853	07/27/2007	1189853	03/11/2008	(005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications; veterinary preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications; biotechnology preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications; medical preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications; diagnostic preparations and reagents for medical purposes; culture fluids, namely, cultures of micro-organisms for medical purposes; human allograft tissue; animal allograft tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells for medical or clinical use; pharmaceutical preparations for the treatment, reconstruction and repair of tissue
PROCHYMAL	Canada	Registered	MESOBLAST INTERNATIONAL SARL	1311540	08/02/2006	TMA821124	03/30/2012	(005 - INTERNATIONAL) Pharmaceutical composition containing mesenchymal stem cells which may be administered intravenously for immune response modulation and to affect tissue repair in treating immune and inflammatory diseases.
PROCHYMAL	Mexico	Registered	OSIRIS THERAPEUTICS, INC.	898498	11/27/2007	1033892	03/31/2008	(005 - INTERNATIONAL) Pharmaceutical composition containing mesenchymal stem cells which may be administered intravenously for immune response modulation and to affect tissue repair in treating immune and inflammatory diseases
RENUMESC	European Union	Registered	MESOBLAST INTERNATIONAL SARL	1491190	08/06/2019	1491190	08/06/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development

REPLICART	Australia	Registered	MESOBLAST LIMITED	1285483	02/18/2009	1285483	10/06/2009	(005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis. medical substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
------------------	-----------	------------	-------------------	---------	------------	---------	------------	---

REPLICART	Canada	Registered	MESOBLAST LIMITED	1448397	08/17/2009	800324	06/20/2011	(001 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis; diagnostic preparations and reagents for medical purposes; culture fluids, namely cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue.
------------------	--------	------------	-------------------	---------	------------	--------	------------	---

REPLICART	Switzerland	Registered	MESOBLAST LIMITED	1016846	08/18/2009	1016846	08/18/2009	(005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis; medical substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
------------------	-------------	------------	-------------------	---------	------------	---------	------------	---

REPLICART China Registered MESOBLAST LIMITED 1016846 08/18/2009 1016846 08/18/2009 (005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, medical substances, diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.

REPLICART European Union Registered MESOBLAST LIMITED 1016846 08/18/2009 1016846 08/18/2009 (005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, medical substances, diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.

REPLICART International Bureau of the World Intellectual Property Organization (WIPO) Registered MESOBLAST LIMITED 1016846 08/18/2009 1016846 08/18/2009 (005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, medical substances, diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.

REPLICART Indonesia Registered MESOBLAST R002019017 11/10/2009 IDW0002999 03/31/2011 19
 (005 - INTERNATIONAL) Pharmaceutical preparations for the prevention - management - diagnosis and prevention of cartilage degeneration young, (2) preparations for prevention of veterinary science - management - diagnosis and prevention of cartilage degeneration young, (3) biotechnology preparations for prevention - management - diagnosis and prevention of cartilage degeneration young, and (4) preparations for prevention of medical science - management - diagnosis and prevention of cartilage degeneration young, (5) medicine substances, (6) diagnostic preparations and reagents for medical science, (7) fluids farming, including the cultivation of micro-organism to medical science, (8) tissues (tendons) human (9) tissues (tendons) animals, (10) tissues (tendons) and human tissues (tendons) animals for transplantation and implantation (implantation), the science of medicine and surgery: (11) human cells, including stem cells (stem), (12) animal cells, including stem cells (stem), (13) the application preparations, re-construction and repair tissues (tendons), (14) vitamins, minerals, preparations containing supplementary nutrition and food additive preparations containing nutrients

REPLICART Japan Registered MESOBLAST 1016846 08/18/2009 1016846 08/18/2009
 (005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, medical substances, diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.

REPLICART Korea, Republic of Registered MESOBLAST 1016846 08/18/2009 1016846 08/18/2009
 (005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, medical substances, diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.


REPLICART Malaysia Registered MESOLAST 9014036 08/18/2009 9014036 05/16/2011 (005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, medical substances, diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded

REPLICART Singapore Registered MESOLAST 1016846 08/18/2009 1016846 08/18/2009 (005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis, and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, medical substances, diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.

REPLICART Thailand Registered MESOLAST 740472 08/18/2009 Kor331977 03/28/2011 (005 - INTERNATIONAL) Pharmaceutical preparations for prevention, management, diagnosis and treatment of osteoarthritis Veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis Substances that are prepared by biotechnology methods for use in prevention, management, diagnosis and treatment of osteoarthritis Medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis Substances that are prepared for use in diagnosis for medical use Medical chemicals used to treat osteomyelitis Substances for culturing microorganisms for medical use Microbial culture for medical use Human tissue cells used in medicine Medical animal tissue cells Human and animal tissue cells are used for transplantation or implantation in the body, medical use, Cells, human tissues and animals used in surgery and medical, medical use Human cells, including medical stem cells Animal cells, including medical cells Substances that are prepared for treatment Rebuilding and repairing tissue cells used in medicine, vitamins, minerals.

REPLICART	Taiwan	Registered	MESOBLAST LIMITED	99003098	01/21/2010	1436371	11/01/2010	(005 - INTERNATIONAL) Prevention, management, diagnosis and treatment of arthritis of the pharmacy; prevention, management, diagnosis and treatment of arthritis veterinary pharmacy; prevention, management, diagnosis and treatment of arthritis of the biological health agents; prevention, management, diagnosis and treatment of arthritis the pharmaceutical preparations; treatment agents and reagents for medical use; medium, that is, microbial culture medium for medical use; medical and surgical transplantation or implantation of human and animal tissues, but not embryonic stem cells; human cells, namely stem cells, but not including embryonic stem cells; animal cells, is the medical or clinical use of stem cells, but not embryonic stem cells; treatment, reconstruction and repair group knowledge of drug preparation, but does not include the preparation of embryonic stem cells.
REPLICART	United Kingdom	Registered	MESOBLAST LIMITED	UK0080101 6846	08/18/2009	UK00801016 849	08/18/2009	(005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, diagnosis and treatment of osteoarthritis, veterinary preparations for the prevention, management, diagnosis and treatment of osteoarthritis, biotechnology preparations for the prevention, management, diagnosis and treatment of osteoarthritis and medical preparations for the prevention, management, diagnosis and treatment of osteoarthritis; medical substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
REVASCOR	United States	Registered	MESOBLAST INC. INTERNATIONAL	77242.134	07/30/2007	4.045.644	10/25/2011	(005 - INTERNATIONAL) Pharmaceutical preparations for the prevention, management, and treatment of connective tissue and musco-skeletal disorders and indications; biotechnology preparations for the prevention, management, diagnosis and treatment of connective tissue and musco-skeletal disorders and indications; medical preparations for the prevention, management, and treatment of connective tissue and musco-skeletal disorders and indications; human allograft tissue; human tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, pharmaceutical preparations for the treatment, reconstruction and repair of tissue
RYONCIL	Australia	Registered	MESOBLAST INTERNATIONAL SARL	2044389	08/23/2019	1492588	08/23/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; advisory and consultancy services in the fields of pharmaceutical research and development
RYONCIL	Canada	PENDING	MESOBLAST INTERNATIONAL SARL	1492588	08/23/2019			(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development

RYONGIL	European Union	Registered	MESOBLAST INTERNATIONAL SARL	1492588	08/23/2019	1492588	08/23/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
RYONGIL	United Kingdom	Registered	MESOBLAST INTERNATIONAL SARL	1492588	08/23/2019	1492588	08/23/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
RYONGIL	United Kingdom	Registered	MESOBLAST INTERNATIONAL SARL	UK00801492588	08/23/2019	UK00801492588	08/23/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
RYONGIL	United Kingdom	Registered	MESOBLAST INTERNATIONAL SARL	UK00801492588	08/23/2019	UK00801492588	08/23/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
RYONGIL	International Bureau of the World Intellectual Property Organization (WIPO)	Registered	MESOBLAST INTERNATIONAL SARL	A0088988	08/23/2019	1492588	08/23/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
RYONGIL	Korea, Republic of	Registered	MESOBLAST INTERNATIONAL SARL	1492588	08/23/2019	1492588	08/23/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
RYONGIL	Switzerland	Pending	MESOBLAST INTERNATIONAL SARL	1492588	10/28/2021			(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
RYONGIL	Turkey	Registered	MESOBLAST INTERNATIONAL SARL	1492588	08/23/2019	1492588	08/23/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes; (042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development

	United States	ALLOWED	MESOBLAST INTERNATIONAL SARL	88317318	02/26/2019			(042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; advisory and consultancy services in the fields of pharmaceutical research and development
	Brazil	Registered	MESOBLAST INTERNATIONAL SARL	918047307	08/23/2019	918047307	04/28/2020	(042 - INTERNATIONAL) Scientific research, clinical research and development in relation to pharmaceutical preparations and medicines; advisory and consultancy services in the fields of pharmaceutical research and development
	Brazil	Registered	MESOBLAST INTERNATIONAL SARL	918047242	08/23/2019	918047242	04/28/2020	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes
	United States	Registered	MESOBLAST INTERNATIONAL SARL	88978590	02/26/2019	6,160,286	09/22/2020	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes
	United States	ALLOWED	MESOBLAST INTERNATIONAL SARL	88346971	03/19/2019			(042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; advisory and consultancy services in the fields of pharmaceutical research and development
	United States	Registered	MESOBLAST INC. INTERNATIONAL SARL	88978866	03/19/2019	6,176,867	10/13/2020	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes
	Brazil	Registered	MESOBLAST INTERNATIONAL SARL	918261198	09/19/2019	918261198	08/23/2020	(42 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
	Brazil	Registered	MESOBLAST INTERNATIONAL SARL	918261040	09/19/2019	918261040	08/23/2020	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes
	Australia	Registered	MESOBLAST INTERNATIONAL SARL	1499741	09/18/2019	2053720	09/18/2019	(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;
	Canada	Pending	MESOBLAST INTERNATIONAL SARL	1499741	09/18/2019			(042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development
	Canada	Pending	MESOBLAST INTERNATIONAL SARL	1499741	09/18/2019			(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;



Switzerland Registered
 MESOBLAST 1499741 09/18/2019 1499741 09/18/2019 (005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;
 (042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development



European Union Registered
 MESOBLAST 1499741 09/18/2019 1499741 09/18/2019 (005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;
 (042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development



United Kingdom Registered
 MESOBLAST 1499741 09/18/2019 1499741 09/18/2019 (005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;
 (042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development



United Kingdom Registered
 MESOBLAST 1499741 09/18/2019 1499741 09/18/2019 (005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;
 (042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development



International Bureau of the World Intellectual Property Organization (WIPO) Registered
 MESOBLAST 1499741 09/18/2019 1499741 09/18/2019 (005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;
 (042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development




Korea, Republic of Registered
 MESOBLAST 1499741 09/18/2019 1499741 09/18/2019 (005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;
 (042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; advisory and consultancy services in the fields of pharmaceutical research and development



Turkey
Published
MESOBLAST
INTERNATIONAL
SARL
1499741
09/18/2019


(005 - INTERNATIONAL) Pharmaceutical, biotechnology and medication preparations and substances for the prevention, management, diagnosis, and treatment of inflammatory and/or degenerative disorders and conditions for medical and surgical purposes;
(042 - INTERNATIONAL) Scientific research, clinical research, and development services in relation to pharmaceutical preparations and medicines; Advisory and consultancy services in the fields of pharmaceutical research and development



United States
Registered
MESOBLAST
LIMITED
79018738
03/30/2005

3,275,342
08/07/2007

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances, diagnostic preparations and reagents for medical purposes, culture fluids, including cultures of micro-organisms for medical purposes; human tissue, animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded;
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to T-cell production, T-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants.



Australia
Registered
MESOBLAST
LIMITED
1028786
10/27/2004

1028786
09/09/2005

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances, diagnostic preparations and reagents for medical purposes, culture fluids, including cultures of micro-organisms for medical purposes; human tissue, animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded;
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to T-cell production, T-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants



International
Bureau of the
World
Intellectual
Property
Organization
(WIPO)

Registered

MESOBLAST
LIMITED

870599


03/30/2005

870599

12/29/2005

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances, diagnostic preparations and reagents for medical purposes, culture fluids, including cultures of micro-organisms for medical purposes; human tissue, animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.;

(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to T-cell production, T-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants.



Brazil

Registered

MESOBLAST
LIMITED

1536538


05/25/2020

1536538

05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances, diagnostic preparations and reagents for medical purposes, culture fluids, including cultures of micro-organisms for medical purposes; human tissue;

(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to t-cell production, t-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animal



Canada

International
Registration
extension pending


MESOBLAST
LIMITED

1536538

05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances, diagnostic preparations and reagents for medical purposes, culture fluids, including cultures of micro-organisms for medical purposes; human tissue, animal tissue; human tissue and animal tissue for transplantation or implantation, medical and surgical purposes; human cells including stem cells, animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.

(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to t-cell production, t-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals, stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants.



European Union

Registered

MESOBLAST LIMITED


1536538

05/25/2020

1536538

05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology; cellular therapies including stem cell therapies and cellular transplants.



India

Registered

MESOBLAST LIMITED


1536538

05/25/2020

1536538

05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology; cellular therapies including stem cell therapies and cellular transplants.



International Bureau of the World Intellectual Property Organization (WIPO)

Registered

MESOBLAST LIMITED


1536538

05/25/2020

1536538


05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology; cellular therapies including stem cell therapies and cellular transplants.




Japan
International
Registration
extension pending
MESOBLAST
LIMITED
1536538
05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants.




Korea,
Republic of
International
Registration
extension pending
MESOBLAST
LIMITED
1536538
05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants.



Singapore
Registered
MESOBLAST
LIMITED
1536538
05/25/2020
1536538
05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology, cellular therapies including stem cell therapies and cellular transplants.



Switzerland

Registered

MESOBLAST LIMITED


1536538

05/25/2020

1536538

05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology; cellular therapies including stem cell therapies and cellular transplants.



United Kingdom

Registered

MESOBLAST LIMITED


1536538

05/25/2020

1536538

05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology; cellular therapies including stem cell therapies and cellular transplants.



United Kingdom

Registered

MESOBLAST LIMITED

UK0080153 6538

05/25/2020

UK00801536 538

05/25/2020

(005 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue; animal tissue; human tissue and animal tissue for transplantation or implantation; medical and surgical purposes; human cells including stem cells; animal cells including stem cells; preparations for the treatment, reconstruction and repair of tissue; vitamins, minerals, nutritional supplements and foodstuffs in this class are excluded.
(042 - INTERNATIONAL) Scientific, research, clinical research, development, advisory and consultancy services in relation to i-cell production, i-cell immunotherapy, cell culture devices, tissue engineering for cellular applications for humans and animals; stem cell banking, tissue banking, drug discovery, vaccine screening, cell culture methods, cell expansion technology including stem cell expansion technology; cellular therapies including stem cell therapies and cellular transplants.



Australia

Registered

MESOBLAST INC. 1022940

09/30/2004

1022940

08/05/2005

(05 - INTERNATIONAL) Pharmaceutical, veterinary, biotechnology and medical preparations and substances; diagnostic preparations and reagents for medical purposes; culture fluids, including cultures of micro-organisms for medical purposes; human tissue.

EXHIBIT D

Mask Works

None.